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Lyme disease is the result of an infection, caused by the Borrelia burgdorferi bacterium, 
which is common in ticks; people can develop Lyme disease after bitten by an infected tick. 
This report describes one of a series of evidence reviews on Lyme disease commissioned by 
the Department of Health (England) Policy Research Programme and undertaken by the 
Department of Health Reviews Facility. This evidence review focuses on the diagnosis of 
Lyme disease. Its aim is to bring together evidence from patients, clinicians and researchers 
about their perspectives on, and experiences of, receiving or delivering Lyme disease 
diagnoses, or evaluating diagnostic tests. As well as being of value in themselves, we aim 
for these syntheses to assist interpretations of evidence about the accuracy of different 
diagnostic approaches.  
Review questions and methods 
The review aimed to address the following questions:- 
 What are patients’, clinicians’ and researchers’ perspectives and experiences of 
diagnosis of Lyme disease?  
 How do these perspectives and experiences help us to understand and implement 
findings about the accuracy of different diagnostic approaches? 
Evidence for this systematic review is drawn from a systematic evidence map which covers 
the range of available research evidence on Lyme disease in humans (Stokes et al. 2017a). 
The evidence map was produced from searches of 17 electronic databases and additional 
web-based searching for unpublished and grey literature. The map includes empirical 
research published from 2002 onwards on Lyme disease in humans. 
For this in-depth review focusing on experiences of Lyme disease diagnosis, studies needed 
to be one of three kinds. One type consisted of diagnostic test accuracy (DTA) studies from 
which we extracted researchers’ comments about barriers and facilitators to the use of 
diagnostic tests in the rationale for their study. The second type were studies that reported 
the views, experiences or behaviours of clinicians with respect to Lyme disease diagnosis. 
The third type were studies that reported the views and experiences of patients with regards 
to Lyme disease diagnosis. All studies needed to describe their methods of data collection 
and analysis. 
Each type of study was synthesised separately to explore different stakeholders’ 
perspectives on Lyme disease diagnosis. The findings of each synthesis were then pulled 
together to examine cross-cutting themes.  
To understand whether our emerging analyses resonated with UK experiences we conducted 
consultation meetings in which we shared our initial findings with eight UK patient advocacy 
groups. Following completion of our analyses we sought comment on the key findings from 
these eight groups via an online survey. 
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Findings 
 Researcher arguments from 33 DTA studies suggest that they perceive that:- 
o Laboratory tests for Lyme disease have significant limitations relating to the 
accuracy of the tests, the timing of tests, a lack of consistency in 
interpretation of test results and the expense and time associated with 
conducting tests. 
o There are challenges for diagnosing Lyme disease arising from variation in 
presenting symptoms. 
o Precise and timely diagnosis is important. 
o There are gaps in the existing evidence base including a lack of good evidence 
for diagnostic tests generally, a lack of evidence for diagnosing Lyme in 
children, a lack of evidence comparing test use in different regions and a lack 
of evidence about tests for specific stages or manifestations of Lyme disease. 
 Nine studies that examined clinicians’ experiences of diagnosing Lyme revealed 
that:-  
o Clinicians develop diagnostic expertise through exposure to cases of Lyme 
and familiarity with the disease, as such their knowledge of the disease varies 
considerably across regions, types of practitioner and in relation to the 
manifestations presented. 
o Clinicians find it challenging to diagnose Lyme disease accurately due to the 
wide variation in symptoms, the infrequency with which they see the disease 
in practice, their level of confidence about being able to diagnose correctly, 
the ambiguity they experience about diagnostic tools and their beliefs and 
behaviour relating to atypical or persistent symptoms. 
o Clinicians access a wide range of sources to help them diagnose Lyme disease; 
sometimes they draw on the patient’s own knowledge. 
 Nine studies on the experiences of patients with persistent symptoms revealed that 
they experienced:- 
o A difficult journey to obtaining a diagnosis and treatment. 
o Ambivalence or scepticism from clinicians. 
o Negative practical consequences such as personal financial burden and costs 
to society. 
o Negative emotional consequences for themselves and their families. 
o Needing to inform themselves about Lyme disease in order to challenge 
clinicians who contested the validity of their symptoms. 
 Feedback from UK patient advocacy groups indicated that these findings largely 
resonated with their experiences. 
 Researchers, clinicians and patients all appear to share a concern that the currently 
available diagnostic tests are not always accurate. 
 Patients and clinicians appear to agree that clinicians lack sufficient knowledge 
about Lyme disease and that uncertainties surrounding Lyme disease can lead to 
tensions in patient-clinician relationships as well as unproductive health care use 
and other costs to society.  
 The evidence base would be strengthened by further qualitative research to explore 
clinicians’ experiences of diagnosing Lyme disease and research with patients who 
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experience a more straightforward diagnosis of Lyme disease. Patient advocacy 
groups noted a need for evidence from the UK. 
Conclusions 
Similar themes were identified between researchers who evaluate diagnostic tests, 
clinicians asked about their experiences of Lyme diagnosis, and people whose diagnosis was 
not straightforward or who identify as having chronic Lyme disease. Future research could 
focus on gaining the perspectives of UK clinicians and patients. Such studies should seek out 
and analyse separately the range of symptoms and/or diagnoses with which patients 




This report is one of a series on Lyme disease commissioned by the Department of Health 
(England) Policy Research Programme and conducted by the Department of Health Reviews 
Facility.  
The overarching project consists of a comprehensive evidence map on Lyme disease in 
humans and four systematic reviews on:- 
1) the incidence and surveillance of Lyme disease 
2) patient, clinician and researcher experiences of diagnosis of Lyme disease 
3) patient, clinician and researcher experiences of treatment and management of Lyme 
disease 
4) prevention of Lyme disease 
This report contains the findings from review 2) on experiences of diagnosis. 
The primary objective of this review is to examine evidence from various stakeholders about 
their experiences of seeking or making a diagnosis of Lyme disease. The aim is to assemble 
evidence of stakeholder views and experiences to assist in the interpretation and 
implementation of evidence about the accuracy of tests for diagnosing Lyme disease.   
1.1 Lyme disease 
Lyme disease is the result of an infection, caused by the Borrelia burgdorferi1 bacterium, 
which is common in ticks; people can develop Lyme disease after being bitten by an infected 
tick (Public Health England 2016).  
In many cases, an early sign of the infection is an erythema migrans or ‘bulls-eye’ rash 
(Stanek and Strle 2003, Wormser et al. 2006). Clinical complications resulting from Lyme 
disease include joint, nervous system, and heart problems (Stanek et al. 2011, Stanek et al. 
2012, Wormser et al. 2006). Some evidence suggests that presentation is not always typical 
(Bingham et al. 1995, Christen et al. 1993) and that complications may be more wide-ranging 
and persistent. However, uncertainties around persistent infection mean that the notion of 
chronic Lyme or post-treatment Lyme disease (PTLD) is contested and has been the subject 
of ‘substantial and polarizing debate’ in the field of medicine for many years (Rebman et 
al. 2017, p535).  
1.2 Diagnosis of Lyme disease 
Current UK guidance (Public Health England 2017) recommends diagnosing Lyme disease 
from patient symptoms when they present with an erythema migrans rash. Laboratory 
testing for Lyme disease is also recommended in cases where an erythema migrans rash is 
                                            
1 We refer here to ‘Borrelia Burgdoferi Sensu Lato’ which includes all sub-species (including afzelii, 
garinii, mayonii, bissettii, lusitaniae and spielmanii). We have used the abbreviated phrase in the 
text for improved accessibility. 
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absent or unclear, but only if patients have both a history of tick bite and other symptoms 
suggestive of Lyme disease such as facial palsy, headache and fever.  
Several international organisations have also produced guidelines and knowledge summaries 
(British Infection Association 2017, Centres for Disease Control 2017, European Centre for 
Disease Prevention and Control 2017, Mygland et al. 2010, NICE 2017d) (NICE 2017a, 2017b, 
2017c), which vary in terms of the symptoms indicating Lyme disease and the interpretation 
of laboratory test values. 
1.3 Using experiential evidence to help interpret and implement evidence of 
diagnostic test accuracy 
Diagnostic test accuracy studies evaluate how well a test is able to correctly identify or rule 
out a disease (Mallett et al. 2012). However, many factors may affect whether and how 
appropriately these tests are used in clinical practice. For example, clinicians may not be 
aware of the circumstances in which testing is appropriate or they may not be aware of the 
significance of the timing of tests. Similarly, patients may have experiences and symptoms 
that differ from typical cases, which makes diagnosis challenging.  
Bringing together evidence from researchers, patients and clinicians about their experiences 
of diagnosis can help to understand the issues that may serve to help or hinder successful 
diagnosis in clinical practice. For example, qualitative evidence syntheses have sought to 
examine patients’ experiences of cancer diagnosis as a result of an emergency presentation 
(Black et al. 2015), the barriers and facilitators to implementing diagnostic guidelines in the 
area of Tuberculosis (Ochodo et al. 2016) and general practitioners’ experiences of 
managing diagnostic uncertainty (Alam 2017).  
1.4 Research on Lyme disease diagnosis 
In 2012 a priority setting exercise was conducted in the UK by The James Lind Alliance 
involving patients, carers and medical professionals who identified 10 priorities for future 
research. Of the ten research priorities identified, the first two focused on the effectiveness 
of laboratory tests currently being used in the UK and the key questions clinicians should 
ask to help make a diagnosis of Lyme disease. Recent systematic reviews have examined 
evidence on the accuracy of laboratory diagnostic tests (Leeflang et al. 2016). The National 
Institute for Health and Care Excellence (NICE) is also currently undertaking a series of 
evidence reviews on the accuracy of both clinical and laboratory approaches for diagnosing 
Lyme disease. 
However, to our knowledge, no previous evidence synthesis has attempted to systematically 
identify and assess evidence of patients’ and clinicians’ experiences of diagnosis.  
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2 Aims and methods 
This section provides a brief overview of the methods used to conduct the review. A detailed 
account of the methods is provided in Section 5. 
The primary objective of this review is to bring together evidence from researchers, patients 
and clinicians about their experiences of receiving, delivering and evaluating diagnoses for 
Lyme disease. The aim of the work is to help to understand the issues that may help or 
hinder the diagnosis of Lyme disease in real-world clinical settings; in particular to help 
interpret and implement evidence about the accuracy of diagnostic tests for Lyme disease. 
2.1.1 Review questions 
The review aimed to address the following overarching questions:- 
 What are patients’, clinicians’ and researchers’ perspectives and experiences of 
diagnosis of Lyme disease?  
 How do these perspectives and experiences help us to understand and implement 
findings about the accuracy of different diagnostic approaches? 
2.2 Methods 
2.2.1 Study identification 
The first phase of the project involved producing a systematic evidence map covering the 
whole range of research evidence on Lyme disease in humans published in or since 2002. We 
sought relevant studies from within the map for this systematic review.   
Full details of the systematic map are available elsewhere (Stokes et al. 2017b). 
2.2.2 Inclusion criteria 
To be included in this evidence review, studies had to be one of the following types:  
 A qualitative or quantitative study published in or since 2002 that reports patient 
views relating to the diagnosis of Lyme disease and which reports methods for data 
collection and analysis. 
 A qualitative study published in or since 2002 or a quantitative study published in or 
since 2008 that reports clinician views, experiences, knowledge or behaviours 
relating to the diagnosis of Lyme disease and which reports methods for data 
collection and analysis. 
 An evaluation of a diagnostic test for Lyme disease included in one or more of the 
NICE evidence syntheses published in or since 2008 that includes informal researcher 
views (i.e. not collected using formal research methods) about factors that help or 
hinder the use of diagnostic tests.  
 
2.2.3 Data extraction, quality appraisal and synthesis 
For the synthesis of researcher arguments, no suitable theoretical framework existed; thus 
thematic analysis, rather than framework synthesis, was used to synthesise findings by 
coding data in individual studies and then iteratively developing themes through 
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examination of commonalities and differences (Thomas and Harden 2008). For the syntheses 
on patient experiences and clinician experiences, framework synthesis was used to 
inductively code and thematically analyse data from qualitative studies and to narratively 
synthesise evidence from surveys (Brunton 2017). In each case, an a priori framework was 
developed based on research team’s expertise and from issues arising in background scoping 
literature. Data were coded into these frameworks and new codes added where new 
concepts arose. For the synthesis of patient experiences, themes were iteratively developed 
from examination of common patterns. For the studies of clinician experiences, higher order 
concepts were drawn out of the data within codes and narratively summarised.  
Findings from all three types of evidence were then compared and contrasted, to identify 
where common themes arose and where differences existed. While we had planned to use 
framework synthesis for all three types of evidence, the nature of the literature meant that 
we were unable to do so. We used pre-existing tools as appropriate for appraising qualitative 
evidence (Garside 2014), (Wong 2008). EPPI-Reviewer software was used for all stages of 
data extraction and synthesis (Thomas 2010).  
2.2.4 Quality assurance 
All studies considered for inclusion in the systematic review were screened by two 
reviewers, who first screened and agreed a subset of references to establish standardised 
screening. Once agreement was reached, pairs of reviewers screened references 
independently. Duplicate data extraction was used initially to standardize reviewers. Once 
standardisation was reached, studies were extracted by one researcher and checked by a 
second. During synthesis, reviewers discussed and resolved any discrepancies and worked 
together to refine emergent themes. 
2.2.5 Consultation with patient advocacy groups and scientific advisory group 
In July 2017 we conducted a series of face-to-face consultations with eight UK-based patient 
advocacy groups. This was done in order to understand how our draft emerging findings from 
international studies of patient views and clinician experiences resonated with UK 
experiences. Participants included both patients and clinicians. Findings from consultations 
were distilled into themes, which were compared to findings arising from studies of patients’ 
views and clinician experiences. Findings were shared with all stakeholders who attended 
consultations to ensure accuracy.  
In October 2017, following the completion of our analyses, we shared the key review findings 
with the patient stakeholder groups. The findings were presented as a series of bullet points 
via an online survey and stakeholder groups were invited to comment.  
We also convened a scientific advisory group (AG) of academics and clinicians with expertise 
in Lyme disease. This group was expected to provide advice on an as-needed basis with 
regard to technical issues relating to the research questions, concepts and definitions, as 
well as strategies for dissemination and impact.  
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3 Findings 
3.1 Overview of included studies  
A total of 310 studies related to diagnosis were identified from the map as potentially 
relevant to our review questions. A total of 61 studies (described in 62 papers) met the 
criteria for inclusion in the review. Our analysis was based on 33 DTA studies, nine studies 
of clinician experiences, and nine studies of patient views. Nine DTA researcher arguments 
studies were not synthesised because thematic saturation had been reached, described 
below. The findings from all three groups of studies are presented below. 
3.2 Findings from researchers’ arguments presented in DTA studies 
3.2.1 Overview of findings from researcher arguments 
 Researcher arguments about diagnosis of Lyme disease were extracted from 33 DTA 
studies; most of the studies were about laboratory diagnosis (n=27), and the 
remainder (n=6) were about clinical or symptom-based diagnosis  
 Arguments about the limitations of laboratory tests for Lyme disease were put 
forward in most studies (n=31); these arguments related to the accuracy of the tests, 
the timing of tests, a lack of consistency in interpretation of test results and the 
expense and time associated with conducting tests 
 Challenges for diagnosing Lyme arising from variation in presenting symptoms were 
noted in 19 studies  
 The importance of a precise and timely diagnosis was recognised in 11 studies 
 Gaps in the existing evidence base were noted in 11 studies, including a lack of good 
evidence for diagnostic tests generally, a lack of evidence for diagnosing Lyme in 
children, a lack of evidence comparing test use in different regions and a lack of 
evidence about tests for specific stages or manifestations of Lyme disease  
3.2.2 Nature of studies included in researcher arguments synthesis 
A total of 42 papers met our inclusion criteria. We extracted data from 33 of these before 
thematic saturation was achieved (i.e. no new patterns or themes were expected to emerge 
from the remaining nine studies; none of which were UK-based). The majority of the 33 
studies focused on laboratory diagnosis; six focused on clinical diagnosis (see Appendix 3 for 
a list of the studies). Clinical diagnosis studies were published between 2008 and 2016; five 
were conducted in Europe and one was from North America. Laboratory diagnosis studies 
were published between 2009 and 2016. Sixteen were conducted in Europe, ten in North 
America and one in Asia. None were conducted in the UK. 
Four broad themes were identified:  
 The limitations of laboratory diagnostic tests 
 The importance of precise and timely diagnosis 
 Lyme disease symptoms made diagnosis a challenge  
 Gaps in the current evidence base.  
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Themes appeared across studies as illustrated in Appendix 2. These four themes are 
discussed in more detail below. 
3.2.3 Theme 1: Limitations of laboratory diagnostic tests 
Authors in almost all studies (n=31) argued that there were limitations to the diagnostic 
accuracy of laboratory tests for Lyme disease, as part of their justification for their study. 
There were four main reasons why laboratory diagnostic testing was considered to be 
problematic. First, there were concerns about the sensitivity and specificity of the tests, 
mentioned by four of the six clinical diagnosis studies and 22 of the 27 laboratory studies. 
For example, one study noted:  
“The diagnosis of LNB poses a challenge to clinicians. Detecting B. 
burgdorferi directly by culture or by PCR from cerebrospinal fluid (CSF) 
yields a maximum sensitivity of only about 50%. The sensitivity and 
specificity of the C6-peptide ELISA in serum have been reported to be 
equal, if not superior, to those of two-tier testing. [However]…data on 
the performance of the C6-peptide ELISA performed on CSF for the 
diagnosis of LNB remain limited and conflicting” (van Burgel et al. 2011). 
Limitations raised by authors about the sensitivity and specificity of the tests focused on 
low test sensitivity, with false negatives (i.e. the result wrongly indicates a person is not 
infected) identified as a particular problem in the early stages of the disease but also 
recognised as a problem in the late stage (Branda et al. 2010, von Baehr et al. 2012). 
Specificity was another challenge, with false positives (i.e. the result wrongly indicates a 
person is infected) resulting from cross-reactivity from antibodies caused by other bacteria 
or viruses, or the persistence of antibodies after the treatment of Lyme disease (Senel et 
al. 2010, Seifert et al. 2016, Tjernberg et al. 2011, von Baehr et al. 2012) and past infections 
(Cerar et al. 2010),  or when there are no longer symptoms (Ang et al. 2015). 
Second, linked to the issue of sensitivity and specificity was the problem that existing tests 
were not reliable for early or late-stage Lyme disease. One clinical study and 17 laboratory 
studies noted the challenge of lab-based diagnostic tests either during the early stages of 
the disease, or for late-stage Lyme disease, using the study authors’ definitions (which 
varied between studies, or in some cases was lacking). For example: 
“standard 2-tiered immunoglobulin G (IgG) testing has performed well in 
late Lyme disease (LD), but IgM testing early in the illness has been 
problematic” (Branda et al. 2010 p.20). 
Third, concerns relating to the variability in the interpretation or reproducibility of 
laboratory diagnostic results were discussed in 12 laboratory studies. These related 
particularly to the Western Blot test and the subjective nature of the interpretation of 
results, variation in criteria and the lack of standardisation between laboratories. For 
example, authors of one study wrote, ‘the difficulty of Western blotting has led to inter-
laboratory and intra-laboratory variation and to false-positive results caused by over- 
interpretation, a particular problem with IgM blots’ q (Branda et al. 2010:p.546). 
Porwancher et al. (2011) also state: 
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“when first introduced for LD diagnosis, whole-cell enzyme 
immunoassays (EIAs) and indirect immunofluorescence assays (IFAs) for 
serum antibodies to Borrelia burgdorferi suffered from a lack of 
standardization, poor reproducibility, and high false-positive rates” 
(p.851). 
Fourth, two clinical and eight laboratory studies referred to the fact that laboratory tests, 
particularly Western Blot, were expensive, labour-intensive, time-consuming (leading to 
delays in treatment) or, for lumbar puncture, painful and invasive.  
3.2.4 Theme 2: The importance of precise and timely diagnosis to inform treatment 
decisions  
Two clinical diagnosis studies (Aucott et al. 2009, Skogman et al. 2015) and nine laboratory 
diagnosis studies cited the importance of precise and timely diagnosis. Authors linked this 
need for ‘early’ detection in children (Lipsett et al. 2016, Skogman et al. 2015) and adults 
(Aucott et al. 2009, Molins et al. 2015, Weiner et al. 2015) with accurate and timely 
treatment decisions overall and made specific reference to the appropriate use of 
antibiotics (Henningsson et al. 2014, Lahey et al. 2015, Skogman et al. 2015, von Baehr et 
al. 2012, Wutte et al. 2011). Henningsson et al. (2014) wrote, for example: 
”a rapid and reliable diagnosis of LNB is essential for patients, since 
delayed antibiotic treatment is associated with slower recovery and 
persistent symptoms” (p.797). 
3.2.5 Theme 3: Wide variety of symptoms makes diagnosis challenging  
Fifteen studies, all six of the clinical studies and 13 of the 27 laboratory studies, raised the 
issue of variation in Lyme symptomology and the challenge it poses for diagnosis. Both 
clinical and laboratory studies, for example, found diagnosis of Lyme disease problematic 
in the absence of, or after the resolution of, erythema migrans (Aucott et al. 2009, Lahey 
et al. 2015, Pomelova et al. 2015, von Baehr et al. 2012, Weiner et al. 2015) when rashes 
are atypical (Aucott et al. 2009, Lahey et al. 2015, Tjernberg et al. 2011); when presenting 
symptoms are nonspecific in adults (Molins et al. 2015), (Senel et al. 2010) (Bil-Lula et al. 
2015, Fallon et al. 2014, Lahey et al. 2015, Ogrinc et al. 2008, von Baehr et al. 2012, Wutte 
et al. 2011) or in children (Skogman et al. 2008, Skogman et al. 2015, Sundin et al. 2012) 
and when symptoms are difficult to distinguish from other causes of illness, in either 
children (Waespe et al. 2010) or adults (Molins et al. 2015). For example, one group of 
authors wrote: 
“many patients who are referred to our Outpatients’ Clinic for suspected 
LB report unspecific symptoms that can be attributed to LB or any other 
disease” (Ogrinc et al. 2008 p.358).  
3.2.6 Theme 4: Gaps in the evidence base  
In eleven studies authors argued that their current study could fill a gap in the evidence 
base. Two studies cite a lack of evidence for diagnostic tests generally (Molins et al. 2015)  
(Ang et al. 2015), or specifically for the C6 Elisa test (Tjernberg et al. 2009). Ang et al. 
(2015) write, for example: 
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“there are few studies that use well-defined patient cohorts and 
compare tests head to head”  (Ang et al. 2015 p.222).  
The general lack of comparative studies of diagnostic specificity is noted by Krbkova et al. 
(2016). In addition, three studies were found to argue explicitly that there is a lack of 
evidence on satisfactory tests, either to identify the infection (Lahey et al. 2015, 
Porwancher et al. 2011) or to confirm ‘early’ Lyme disease in the absence of erythema 
migrans (Aucott et al. 2009). Two studies reported a lack of evidence comparing tests from 
different geographical areas (Ang et al. 2015, Branda et al. 2010). Five studies argued there 
was a lack of evidence on the detection of Lyme in children (Lipsett et al. 2016, Skogman 
et al. 2015, Sundin et al. 2012, Tveitnes et al. 2012, Waespe et al. 2010). The point was 
made that, although there is evidence for adults, there is a lack specifically for children, 
for either the C6 EIA test (Lipsett et al. 2016) or the occurrence of long-term neurological 
deficits caused by tick-borne CNS infections (Sundin et al. 2012). Similarly, Tveitnes et al. 
(2012) explained that although 
“Research has aimed to develop models for the prediction of LM [Lyme 
meningitis] in these children, no such studies have been performed in a 
fully population based setting in an endemic area for LB” (p.215). 
3.2.7 Patient advocacy group views on these findings 
Four main arguments were used by researchers to justify the need for a study on diagnosis: 
that laboratory tests for Lyme disease are limited, that precise and timely diagnosis is 
important, that Lyme disease symptoms make diagnosis a challenge and that there are gaps 
in the evidence base around Lyme disease diagnosis. Few responses to our survey of key 
findings in October 2017 were specifically about the findings from researcher arguments. 
However, during our face-to-face consultations with groups in July 2017 several of the issues 
raised by patient advocacy groups corresponded with these findings.  
First, several groups discussed the limitations of existing laboratory tests for Lyme disease 
and the overreliance of clinicians on these tests for both supporting and excluding a 
diagnosis of Lyme disease. In two consultations, the limitations of testing for antibodies as 
opposed to the Borrelia organism itself was raised. In several consultations variability in 
interpretation of test results was raised, and two stakeholders raised concerns about a lack 
of knowledge or consistent practice in storing and transporting blood samples. Also in line 
with the researcher arguments synthesis was a concern for many participants around the 
timeliness of testing and diagnosis. Participants also had concerns about the barriers to 
conducting useful research (discussed further below) which appear to mirror researchers’ 
concerns about gaps in the research; in particular several stakeholders described a need for 
rigorous evaluations of alternative tests (i.e. not those used as standard by the NHS). 
3.3 Findings from studies of clinician experiences 
3.3.1 Overview of findings from studies of clinician experiences 
 Nine studies of non-UK origin were identified that examined clinicians’ experiences 
of diagnosing Lyme: eight of these were surveys of knowledge, attitudes and 
behaviour and one was a qualitative study of clinicians’ views about learning to 
diagnose Lyme disease 
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 Findings suggest that clinicians develop familiarity and expertise with Lyme disease 
in order to diagnose it, but that their knowledge of the disease varies considerably 
across regions, types of practitioner and in relation to the manifestations presented 
 Clinicians find it challenging to diagnose Lyme disease accurately due to the wide 
variation in symptoms, the infrequency with which they see the disease in practice, 
their level of confidence about being able to diagnose correctly, the ambiguity they 
experience about diagnostic tools and their beliefs and behaviour relating to atypical 
or recurring symptoms 
 Despite these challenges, clinicians access a wide range of sources to help with 
diagnosis; sometimes involving the patient 
3.3.2 Nature of included studies 
Nine studies examining clinicians’ experiences with diagnosing Lyme disease were included 
in the review (see Appendix 4 for a list of the studies). Study aims varied. Most explored 
practitioners’ knowledge and practices so as to understand adherence to recommended 
guidelines for Lyme diagnosis and treatment (Brett et al. 2014, Esposito et al. 2013, Henry 
et al. 2012, Hill and Holmes 2015, Johnson et al. 2010, Singh et al. 2016). Four studies 
sought to understand the frequency with which practitioners encountered Lyme disease and 
the impact on knowledge and skills (Brett et al. 2014, Ferrouillet et al. 2015, Johnson et al. 
2010, Singh et al. 2016). Only one qualitative study was identified (Bakken 2002). Here 
authors aimed to understand how practitioners learned to diagnose Lyme disease in order 
to provide a theoretical framework for designing future medical practitioner education. 
Finally, one study examined the impact of different serological test thresholds on the 
clinical practice of infectious disease specialists (Hansmann et al. 2014). Studies were 
conducted in the US (n=5), Canada (n=2), France (n=1) and Italy (n=1). No UK studies of 
clinician experiences were located. Two studies sought the experiences of infectious disease 
specialists only and one surveyed general practitioners only; the remaining included studies 
included practitioners from a range of specialisms.  
Four studies were considered to be of high quality (Bakken 2002, Brett et al. 2014, Henry et 
al. 2012, Hill and Holmes 2015), with the remaining five studies of low quality (Esposito et 
al. 2013, Ferrouillet et al. 2015, Hansmann et al. 2014, Johnson et al. 2010, Singh et al. 
2016). Lower quality ratings in the quantitative studies were largely due to non-probability 
sampling (n=5 studies), a response rate below 70% (n=7 studies), and no description of 
control for confounding factors (n=6 studies). Detailed quality assessment ratings for each 
of these studies is provided in Appendix 5.  
Data from the nine studies were captured under four categories: knowledge, attitudes, 
behaviours, and other issues. The issues seen within each of these categories gave rise to 
several sub-categories, which resulted in the development of three overarching themes: (1) 
familiarity and expertise; (2) diagnostic uncertainty; and (3) navigating uncertainty. These 
are discussed below.  
3.3.3 Theme 1: Familiarity and Expertise 
Bakken (2002) reports that clinicians undergo a process of learning to diagnose Lyme disease 
that is built upon gaining familiarity with the disease presentation, observing a range of 
cases in order to get familiar and then putting it together using a patient’s history and 
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background. However the extent to which clinicians see patients with Lyme disease varies 
by location and the type of practitioner. Knowledge of Lyme disease etiology, epidemiology, 
signs and symptoms and diagnostic test processes were assessed across studies. Findings 
across this set of studies suggested clinician knowledge of all of these dimensions was 
incomplete and varied considerably within each dimension. While three studies reported 
overall high knowledge scores (between 72% and 75%) about Lyme disease, it was suggested 
the clinicians had knowledge gaps because clinicians did not answer all questions correctly 
(Ferrouillet et al. 2015, Henry et al. 2012, Hill and Holmes 2015). For example, while two 
studies reported very high levels of knowledge that Lyme disease was caused by Borrelia 
burgdorferi (96%-99%), generally only moderate levels of knowledge were reported with 
respect to the incubation period and knowledge of when to test and to follow-up (50%-84%) 
(Henry et al. 2012, Singh et al. 2016). While studies used the terms ‘prevalence’ (number 
of individuals with a disease at one given time), ‘incidence’ (the number of individuals who 
contract a disease over a period of time) and ‘endemic’ (the regular presence of disease in 
a given area) interchangeably, clinician knowledge about whether Lyme disease was 
endemic or highly prevalent in their region varied from 51% to 78% across studies, and 
appeared linked to whether clinicians were from a high or low prevalence area (Ferrouillet 
et al. 2015, Henry et al. 2012, Hill and Holmes 2015). Further, in regional studies of areas 
of high and low prevalence, fewer clinicians reported knowing their region was of high 
prevalence, with scores between 25% and 28% (Henry et al. 2012, Hill and Holmes 2015). 
Knowledge scores ranged from 10% to 66% in studies where clinicians were asked to identify 
endemic regions in areas adjacent to or in other countries (Ferrouillet et al. 2015, Henry et 
al. 2012). Where clinicians had this knowledge, Bakken (2002) noted that they used this 
information to their advantage when establishing a differential diagnosis:  
“If somebody comes in with, since we’re talking about Lyme disease, a 
funny rash… erythema marginatum. If you see that, you know that this 
is a family who has a cabin up north… You know some of those things. 
While that family probably would be acquainted with Lyme disease,… 
then you could say, ‘Well, couldn’t you have had a tick bite?’ … ‘Oh, 
sure.’” (p.135) 
Knowledge of common symptoms of Lyme disease (i.e. erythema migrans) appeared to be 
moderate. This varied across the studies according to whether the region of practice had a 
high prevalence of tick bites. For example, in one study set in an area of high prevalence, 
only 56% of respondents reported knowing that erythema migrans alone was diagnostic for 
Lyme disease (Singh et al. 2016). For recognition of more uncommon symptoms of Lyme 
disease, such as arthritis, fever, radiculoneuropathy, meningitis and heart block, participant 
responses also varied according to the type of clinician. It appears that 63% to 99% of 
specialists were more likely to demonstrate knowledge of uncommon symptoms (Henry et 
al. 2012), with only 5% to 14% of general practitioners reporting similar knowledge 
(Ferrouillet et al. 2015). 
Bakken (2002) noted that clinicians needed to encounter many patients with Lyme disease 
symptoms in order to experience the wide variability in symptoms. However, clinicians 
across the surveys reported seeing Lyme disease fairly infrequently. Those in areas of high 
prevalence reported more experience (Brett et al. 2014, Ferrouillet et al. 2015). In one 
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study, only 61% of infectious disease specialists reported seeing patients suspected of having 
Lyme disease less than once per month (Hansmann et al. 2014). While some authors 
suggested that the number of patients seen and the prevalence rates in the area of practice 
were not associated with higher knowledge scores, data were not presented to support this 
finding (Singh et al. 2016). 
These factors were all suggested to influence overdiagnosis, underdiagnosis and incorrect 
treatment in relation to recommended guidelines. Many of the studies sought to assess 
clinician knowledge of correct management of diagnosis and treatment of Lyme disease. 
Across the studies, authors reported very low levels of knowledge of correct management. 
For example, two studies reported that only between 5% and 18% of clinicians would 
correctly prescribe antibiotics without a blood test for a patient presenting with a bull’s eye 
rash and tick removal (Brett et al. 2014, Ferrouillet et al. 2015). Other studies suggested 
that knowledge of correct management differed by type of clinician; however, some claimed 
that general practitioners demonstrated higher correct management (Singh et al. 2016), 
while others asserted that rates were roughly similar, with specialists having slightly greater 
knowledge (Henry et al. 2012). These findings may have been due to geographic differences 
in the studies’ samples: Henry et al. (2012) sampled across a Canadian province, suggesting 
a potentially more representative sample, while Singh et al. (2016) sampled from one 
regional medical centre. Years of practice may also influence correct management: one 
study found that clinicians who had been practising longer were more likely to incorrectly 
perform additional diagnostic tests if the first test for Lyme disease was positive (Hill and 
Holmes 2015). 
The lack of exposure to patients presenting with Lyme symptoms appeared to lead clinicians 
to overdiagnose or overtreat patients. Studies noted examples of this, including 75% 
incorrectly ordering screening tests for patients with erythema migrans rash (Brett et al. 
2014, Esposito et al. 2013); incorrect ordering of repeat serology for children presenting 
with Lyme arthritis in non-endemic areas and inappropriate use of Polymerase Chain 
Reaction (PCR) testing for children presenting with either Lyme arthritis or neuroborreliosis 
symptoms (Esposito et al. 2013). Studies also described 33% of clinicians treating patients 
inappropriately for Lyme disease in a region with low prevalence (Brett et al. 2014); 31% 
ordering post-tick bite prophylaxis in the absence of symptoms (Brett et al. 2014); and 
moderate use of appropriate antibiotic treatment in children with erythema migrans rash 
(Esposito et al. 2013). In another study, almost 40% of respondents in one study reported 
initiating treatment for Lyme disease, despite a belief that the patient may not have the 
condition (Hill and Holmes 2015). 
3.3.4 Theme 2: Diagnostic Uncertainty 
As clinicians gain experience in diagnosing Lyme disease, they report encountering 
considerable clinical, personal and practice uncertainties. Clinically, the symptoms appear 
to vary widely, from those that occur in the majority of cases (i.e. erythema migrans), to 
those which occur less frequently (i.e. cardiac, neurological and arthritic involvement), to 
those which are atypical or may mimic other conditions (i.e. atypical rash, fatigue, joint 
pain, fever, weakness), to those which persist after treatment has occurred.  
Clinicians need to have confidence in their abilities to detect Lyme disease. However, across 
the studies clinicians appeared to vary in their belief about their ability to correctly diagnose 
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the condition. Almost 70% of responding clinicians in one state-wide study agreed or strongly 
agreed that they were knowledgeable about Lyme disease (Brett et al. 2014). In another, 
high proportions of infectious disease specialists in one clinic saw their role as ‘experts’ who 
should  
“put an end to long series of investigations, specialized consultations 
and…useless or deleterious antibiotic therapies” (Hansmann et al. 2014 
p.202 - 203).  
In contrast to these findings, authors elsewhere noted that over 84% of general practitioners 
expressed a need for further information about symptoms, lab tests and treatment 
(Ferrouillet et al. 2015). 
In terms of practice uncertainties, the screening tests themselves created uncertainty for 
some clinicians. Some studies indicated that uncertainties existed amongst some clinicians 
around the reliability and validity of the diagnostic tests themselves. Hill and Holmes (2015) 
reported that 51.8% of clinicians considered the diagnostic tests currently in use to be 
unreliable. Hansmann et al. (2014) studied the impact of one private laboratory’s lower 
diagnostic thresholds and ‘subjective’ interpretation for Lyme disease on infectious disease 
specialists’ practice. Here, patients with both positive and negative lab results presented 
with symptoms, some of whom had been treated but were still consulting infectious disease 
specialists because symptoms had not resolved. Authors suggested that seeking out positive 
lab results from a private lab with lower diagnostic thresholds resulted in ‘useless antibiotic 
therapies…that failed to solve the patients’ problems, since they continued consulting 
specialists for an effective treatment.’ (p.203).  
Patients’ symptoms also created uncertainty. Five of the studies reported or suggested a 
belief amongst some clinicians that the patients' symptoms were caused by something other 
than Lyme disease (Bakken 2002, Hansmann et al. 2014, Henry et al. 2012, Johnson et al. 
2010, Singh et al. 2016). Bakken (2002) describes this most clearly: 
“…but Lyme disease in practice appears to include such a high degree of 
variability, even to the point where there are hundreds, thousands of 
folks who believe they have Lyme disease, who have almost no findings 
at all. (Dr. NE)” (p.136) 
Another study assessed clinicians’ diagnostic and treatment behaviours based on their belief 
in the existence of ‘chronic’ Lyme disease, defined as persistent Borrelia burgdorferi 
infection requiring long term oral and/or intravenous antibiotic therapy (Johnson et al. 
2010).  Only 2% of responding clinicians reported a belief in chronic Lyme disease, with 48% 
undecided and 50% reporting they did not believe it was a condition.  
Reluctance to attribute presenting symptoms to Lyme disease or scepticism about the 
existence of ‘chronic’ Lyme disease appeared to lead to differences in management. In one 
study, a small proportion of clinicians (30% of general practitioners and 12% of specialists) 
still treated patients, despite believing the person did not have the disease (Henry et al. 
2012). In contrast, authors in another study suggested that the end result of patient 
consultations based on inaccurate lab tests was ‘useless antibiotic treatment’ and the 
‘continued consultation of specialists’ (Hansmann et al. 2014). Others claimed that patients 
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who presented with what they termed ‘chronic’ Lyme disease ‘were not helped by the oral 
and intravenous antibiotics, and sometimes underlying diagnoses, such as depression and in 
one case leukaemia, were missed.' (Johnson et al. 2010 p.1028). 
3.3.5 Theme 3: Navigating Uncertainty 
In order to navigate the uncertainty presented by the setting in which they practice, their 
previous experience with the disease, the wide variety of symptoms presented by patients 
and the challenges to diagnostic tests and consultation processes, clinicians reported using 
a variety of methods to help them diagnose Lyme disease.  
Bakken (2002) described clinicians needing some time to consider a patient’s case before 
making a diagnosis. Respondents described using strategies such as looking farther back in 
a patient’s history in order to decide on the most appropriate specialist for referral, 
reviewing a patient’s notes, discussing the case with a colleague or consulting a research 
article. A wide variety of sources of information were also described across two studies 
(Brett et al. 2014, Ferrouillet et al. 2015), with websites commonly cited across all types of 
clinicians in one state-wide survey, but most likely to be utilised by clinicians who 
encountered Lyme disease infrequently (Brett et al. 2014). Professional meetings were 
preferred by older clinicians and dermatologists, and in those who saw more than 100 
patients per week (Brett et al. 2014). Another study noted that general practitioners 
preferred continuing medical education (73%) and medical literature (63%)(Ferrouillet et al. 
2015). 
Patients themselves could also be a source of learning, reportedly bringing information 
about Lyme disease to the clinical encounter (Bakken 2002, Hill and Holmes 2015). In one 
study, 52% of participants reported that patients had brought up Lyme disease as a possible 
diagnosis (Hill and Holmes 2015). Elsewhere, clinicians reported co-investigation by patients 
and clinicians, with patients raising the possibility of Lyme disease themselves: 
“…I said, ‘I’ll tell you what, I’m going to have to do some more research 
on this, but this bugs me that I can’t remember what it is’, so I sent him 
out and said I want to see you back in a week. And he was . . . other than 
the rash, he had no problem. He called me back in 2 days and he said, ‘1 
think I may know what I have.’  And I said, ‘You have Lyme disease.’ And 
he said, ‘Yes.’ (Dr. GS)’” (Bakken 2002) p.137 
3.3.6 Patient advocacy group views on these findings 
Patient advocacy group feedback on these findings from both the face-to-face consultations 
and the online survey is reported below.   
Feedback on clinician experiences theme 1: Familiarity and expertise 
Many of the stakeholders felt patients often encountered a lack of knowledge among 
clinicians. This was particularly emphasised in relation to the recognition of signs and 
symptoms, in particular a ‘staggering ignorance’ about erythema migrans, for example in 
terms of recognising atypical rashes or knowing some infected patients do not have a rash. 
Stakeholders also reported experiences indicating a lack of awareness among clinicians 
about areas in which Lyme is endemic, or current guidance for diagnosis and treatment. For 
example, several groups raised the issue of clinicians ordering unnecessary blood tests for 
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patients presenting with erythema migrans or ordering tests too early, before antibodies 
have a chance to develop. Others raised the issue of a lack of awareness among clinicians 
that Lyme disease can be acquired throughout the UK.  
Feedback on clinician experiences theme 2: Diagnostic uncertainty  
Several of the patient stakeholders and all of the clinicians recognised the challenges placed 
on clinicians by the varied nature of signs and symptoms of Lyme disease. One patient 
advocacy group member described trying to convey this to group members:- 
“I say try to imagine you’re doctor that has only seen three Lyme disease 
patients before, with symptoms that could be caused by a hundred different 
things, would you be confident making a clinical diagnosis of Lyme disease?” 
Nevertheless, many of the groups also indicated a view that clinicians needed to 
acknowledge and communicate their uncertainty to patients. For example, several 
stakeholders were of the view that clinicians were over-reliant on test results, for example 
‘So many doctors are sure that NHS testing or other tests should not be questioned. That 
is not how we do science.’ 
Another stakeholder noted that:- 
“We need to remember we’re dealing with a complicated illness – there 
wouldn’t be all of this politics around it if we knew exactly how to test for 
the bacteria and we knew how to treat with success across the board.” 
Feedback on clinician experiences theme 3: Navigating uncertainty  
Whilst many stakeholders recognised the challenges faced by clinicians in obtaining 
sufficient knowledge, they also felt that the political climate surrounding Lyme disease in 
the UK was not conducive to learning as it hampered both clinical practice and research. 
For example:-  
“Until we become more open-minded nothing will change, but no one 
wants to step out of line.” 
In relation to research, several stakeholders indicated that researchers are reluctant to 
address important questions for patients, with one referring to the lack of relevant research 
as ‘institutional denial’. One stakeholder noted that there was only one registered medical 
practitioner from the UK at a global conference where current treatments and new research 
were being discussed. A key perceived impediment to research was possible harm to 
researchers’ and clinicians’ careers:- 
“There are very few papers that look at harm to patients from misdiagnosis 
– why is that? It’s because nobody is going to enhance their career if they 
publish a paper that illustrates that their profession is failing patients.” 
Both patients and clinicians involved in the July 2017 consultations recognised that similar 
constrains hindered practice. Many described clinicians feeling anxious about losing their 
licence to treat, being vilified by their profession or being ‘chased’ by authorities.  
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“There are doctors who have been chased by GMC for trying to do a bit more. 
You’re really putting things on the line by trying to push the limits of what 
you can give a patient.” 
Some indicated that another barrier to increased knowledge was the loss of both clinicians 
and patients to other countries. For example:- 
“I think we are missing valuable information in the UK with so many seeking 
diagnosis, testing and treatment overseas because they aren’t getting 
answers here in the UK.” 
Stakeholders from four groups specifically contested the finding that clinicians’ welcome 
information about Lyme disease from patients. One described this finding as being ‘at odds 
with UK patient experience’ and another noted that ‘clinicians tend to be defensive in the 
face of patient knowledge, often advising patients not to educate themselves on the 
internet.’ 
One stakeholder, in describing the range of clinician attitudes and knowledge, summed up 
the consequences for patients of constraints to knowledge and practice:- 
“There’s an arrogance amongst some, a limited knowledge amongst others 
or there are those who are more open-minded but feel their hands are tied.” 
 
3.4 Findings from studies of patient views and experiences 
3.4.1 Overview of findings  
 Nine studies which discussed the patient experience of Lyme disease were identified; 
all of these focused on experiences of patients for whom diagnosis was not 
straightforward or who had persistent symptoms 
 The patients described a range of consequences of living with a condition that is 
contested and controversial including:- 
o Their concern to obtain a diagnosis and the difficulties of achieving this 
o Ambivalence from medical practitioners 
o Negative practical consequences such as financial burden 
o Negative emotional consequences for them and their families 
o Ways in which they challenged the contested nature of their condition 
3.4.2 Nature of the included studies 
We found nine studies reported in ten papers which discussed the patient experience of 
Lyme disease; Appendix 6 provides an overview of the included studies. Critical assessment 
of the studies was undertaken using the tool presented in Appendix 7. Studies were of low 
to moderate quality overall, with gaps noted most often in reporting of epistemological and 
theoretical underpinnings. Quality ratings are summarised in Appendix 8.  
All of the studies focused on patients who had experienced persistent symptoms. Thus, the 
literature contained in this synthesis relates to the experiences of a particular group of 
Lyme patients whose journey was not straightforward. The experiences of those who were 
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diagnosed and treated promptly and who experienced no ongoing problems are notably 
absent from this research evidence. 
In understanding the context of these findings, it is also important to understand the 
position of the study authors, given the divergent views about the existence of legitimacy 
of persistent Lyme disease symptoms. Eight of the studies indicated that they ascribed to a 
heterodox perspective (Ali et al. 2014, Bloor and Hale 2013, Chaudhury 2016, Dankyi 2016, 
Drew and Hewitt 2006, Johnson et al. 2014, Johnson et al. 2010, Rebman et al. 2015). In 
other words, the authors described Lyme disease, in contrast to many medical guidelines, 
as a complex condition with various symptoms, which has the potential for long-term 
complications and which is often misdiagnosed or under-diagnosed. Only one study took an 
orthodox perspective (Csallner et al. 2013) viewing Lyme disease as a straightforward, acute 
infection which is easily diagnosed and successfully treated.  
In terms of participants, seven of the papers (all categorised as heterodox) were unclear as 
to the diagnostic status of their sample, with some stating that it was not a matter of 
concern for their paper, since their focus was on the lived experience of the disease (Ali et 
al. 2014, Chaudhury 2016, Dankyi 2016).  Patients in six of these studies were recruited from 
patient support groups and the other via a ‘home infusion company’ treating patients with 
persistent symptoms. Rebman et al. (2015) was the only study classified as heterodox to 
focus on patients with verified clinical and serological diagnosis. The one paper classified 
as orthodox (Csallner et al. 2013) recruited patients referred to a Lyme clinic and compared 
the views of those with a positive Lyme disease test result to those with a negative one; 
therefore, the orthodox diagnosis of Lyme disease became the central explanatory variable 
for their results. 
3.4.3 Theme 1: The difficult path to diagnosis: “It’s not this invisible thing anymore.” 
(Drew and Hewitt 2006 p.24).  
 The process of obtaining a diagnosis of Lyme disease when clinical 
markers are unclear or atypical can be a highly charged experience, 
leaving the patients fraught with uncertainty and frustration.  
 The legitimacy ascribed by an official diagnosis leads to relief from 
uncertainty and opened up access to treatment and care.  
The first key theme arising from the research with patients was that they were keen to 
receive a correct diagnosis so that they could access appropriate treatment and have their 
symptoms resolved. However, the research also indicated that the process of obtaining a 
diagnosis was often difficult and lengthy. Patients emphasised the emotional impact of 
seeking and receiving a diagnosis. Respondents expressed relief if they did receive a 
diagnosis, since it put an end to uncertainty and validated their experience of the illness:  
 
“He tested me for it and it came back positive.  I was pleased.  I can hold 
this now.  I can deal with it.  We’re gonna treat it.  It’s not this invisible 
thing anymore […] I just felt like, oh my God, someone believes me.” 
(Drew and Hewitt 2006 p.24). 
 
For many patients however, diagnosis was not so straightforward. The tell-tale rash 
erythema migrans, a key marker for a clinical diagnosis, was missing (43%) or not typical 
(17%) for patients in a UK survey (Bloor and Hale 2013). In this survey, less than half (48%) 
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of the respondents remembered the bite, whilst the remaining 52% couldn’t remember, 
weren’t sure they had been bitten or thought they may have caught the disease in another 
way (Bloor and Hale 2013). Respondents in the Chaudhury (2016) study also described 
unclear memories of tick bites.  
 
Uncertainty about infection or untypical symptoms could lead to frustration as it could be a 
factor in a delayed diagnosis (Drew and Hewitt 2006). Delays were attributed to visiting 
multiple centres where specialists conducted their own tests to rule out other diseases, such 
as multiple sclerosis (Chaudhury 2016, Dankyi 2016):  
 
“Like many chronic Lyme disease patients, I was launched into a medical 
maze, searching for answers as things worsened. I told my husband that 
something in my body had broken. It was falling apart. I went to 
specialist after specialist, and each one found some possible cause within 
his or her specialty.”(Chaudhury 2016 p.29)  
The multiple tests used to verify infection and disease were described as leading to long 
delays in receiving treatment (Bloor and Hale 2013, Chaudhury 2016, Dankyi 2016, Drew and 
Hewitt 2006, Johnson et al. 2014, Johnson et al. 2010). Johnson et al. (2014) reported that 
for 61.7% of respondents there was a wait of at least two years. Some respondents described 
difficulty in persuading doctors to do the testing for Lyme disease (Dankyi 2016). As a result, 
some ambivalence about the testing process was expressed: 
 
“They kept doing all this blood work over and over and over and 
everything, liver, kidneys, immune, everything they could do and 
everything is coming back negative….extremely frustrating.” (Drew and 
Hewitt 2006 p.23) 
3.4.4 Theme 2: Ambivalence from clinicians – “The thing that upset me the most about 
the whole thing was what a political football it is.” (Rebman et al. 2015 p.8) 
 Many patients indicated that they felt they were denied a diagnosis by 
clinicians who questioned the legitimacy of persistent symptoms of Lyme 
disease. 
 As a result patients indicated that doctor-patient relationships could be 
strained.  
 Many patients perceived that clinicians often undermined the legitimacy 
of their illness by implying that their problems were psychosomatic, 
therefore leading to further uncertainties and potentially more 
misdiagnosis.   
The second key theme from the patient views research was that many clinicians were 
perceived as ambivalent, sceptical or even hostile to the idea of persistent symptoms of 
Lyme disease. Whilst patients in one study described attributes of helpful doctors as ‘open-
minded’, ‘supportive’ and willing to ‘acknowledge patient concerns’ (Ali et al. 2014), 
patients in several studies described experiencing doctors to be ‘dismissive’, 
‘condescending’ or ‘patronizing’ (Ali et al. 2014, Bloor and Hale 2013, Dankyi 2016). 
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In the study by Rebman et al. (2015) one patient described chronic Lyme as a ‘political 
football’, while another recalled an instance where their therapy was questioned by a doctor 
in an encounter at a dinner party:  
“We were having dinner […] I said you know I have chronic Lyme disease, 
and his immediate reaction was just sort of to pull back from the table 
and he said well, who told you that? And I explained you know, what had 
been going on and all this time and he said well, I don’t think that 
evidence supports what you’re doing.” (Rebman et al. 2015 p.8)  
Patients were wary of the imputation of a psychological cause to their suffering since it 
seemed to suggest that their illness was illegitimate (Chaudhury 2016). A parent in one study 
expressed frustration at the constant uncertainty expressed by clinicians describing it as:- 
 “…this shadow disease where people are constantly questioning you and 
questioning your child.” (Dankyi 2016 p.67) 
Published in the journal ‘Psychosomatics’, the article by Csallner et al. (2013) underscores 
these patients’ perceptions that some see their illness as illegitimate. The authors suggest 
that patients ‘claim to suffer from “chronic Lyme disease”’ and that this leads to:- 
“Inappropriate use of health services, avoidable treatment-related 
illness, and substantial disability and distress”. It has been repeatedly 
suggested that “Chronic Lyme Disease” is just another unwarranted label 
for “organically unexplained symptoms (OUS).” (Csallner et al. 2013 
p.360)  
3.4.5 Theme 3: Practical consequences of ‘living in limbo’ – “I have already reached my 
out-of-pocket max” (Ali et al. 2014 p.4) 
 Patients whose symptoms remained undiagnosed and unresolved could suffer long 
term negative financial consequences such as: ongoing medical bills, travelling long 
distances for care, prolonged absences from work.  
 The negative consequences were not only borne by the patients themselves, studies 
indicated societal impacts including increased used of healthcare resources and 
patients turning to higher usage of complementary alternative therapies, which can 
also be expensive.  
The third theme arising from the patient views research was that patients with persistent 
symptoms, and particularly those without an official diagnosis, could experience negative 
consequences with regards to their livelihoods. All of the papers from the USA, where 
healthcare is paid for by insurance, commented on the financial burden of the disease for 
patients (Ali et al. 2014, Dankyi 2016, Drew and Hewitt 2006, Johnson et al. 2014, Johnson 
et al. 2010). Johnson et al. (2014) reported higher out-of-pocket expenses than the general 
population for medicines and treatments, with 69% spending more than USD$2,000 a year, 
compared to 20% of the general population spending that amount. For example:- 
“Even though insurance pays for this … I have already reached my out-of-
pocket max and it’s August. I met it last month and that’s $2500. That 
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doesn’t include other prescriptions or co-pays for August visits.” (Ali et 
al. 2014 p.4)  
Costs were also incurred in travelling for care. Many respondents found it difficult to obtain 
care at their local hospital and some described travelling some distance to find doctors 
willing to treat them (Johnson et al. 2010). The seeking out of diagnosis or treatment that 
was not officially recognised could have further financial consequences; one study reported 
that patients were either not covered by insurance because their doctors were outside state 
borders or the treatment was considered experimental (Drew and Hewitt 2006).  
These costs were particularly problematic since many could no longer work (Drew and 
Hewitt 2006, Johnson et al. 2010); and others reported that their retirement savings had 
been spent (Dankyi 2016). Johnson et al. (2014) reported that 42% of respondents had 
stopped working as a result of illness, while 25% had reduced their hours or changed the 
type of job they were doing. A quarter of survey respondents indicated that they had 
received benefits at some point, and more than half had had disability benefits for over two 
years (Johnson et al. 2010). This impact on ability to work and productivity thus has 
consequences for employers and for the state.  
Another consequence of being left ‘in limbo’ (Rebman et al. 2015) in terms of societal costs 
was that patients were more likely to use health services more (Csallner et al. 2013, Johnson 
et al. 2014). Johnson et al. (2014) found that chronic Lyme disease patients were five times 
more likely than the general population to visit doctors and healthcare professionals and 
twice as likely to visit the emergency department of a hospital. They also spent more time 
in hospital (15.2% vs. 7.9%) and had six times more homecare visits (12.8% vs. 2%).  
3.4.6 Theme 4: The emotional consequences of living with a contested condition: “People 
do not believe me about how bad I feel.” (Rebman et al. 2015 p.7) 
 Patients reported poor mental health, and negative emotional and social impacts  
The personal costs of living with a contested illness were not purely limited to financial 
costs. Csallner et al. (2013) found scores on a scale measuring ‘excessive health worry’ were 
higher among those without a diagnosis than those whose test results were positive; they 
also had much lower scores on measures looking at quality of life. These findings reflect the 
experiences of the patients from other studies, who report higher than average physical and 
mental illness events, such as days lost to pain and mental distress (Johnson et al. 2014) or 
anxiety and depression (Ali et al. 2014, Chaudhury 2016, Rebman et al. 2015). 
Patients attest to the psychological aspects of living with persistent symptoms; in their 
accounts of dealing with the chronic nature of the disease, they acknowledge the emotional 
toll it can take and experiencing a sense of loss for the life before their illness (Chaudhury 
2016, Rebman et al. 2015): 
“I’ll say, ‘oh, I know I’m accepting it much more’ but I realize that when 
I hit a wall again and I get really disappointed all over again, I realize you 
weren’t accepting this as much as you said you were. I mean, I think we 
can kid ourselves.” (Rebman et al. 2015 p.6) 
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In these accounts, the patients do not discuss tick bites, the results of serological tests or 
erythema migrans. Their concerns are about the problems of living with the illness, 
compounded by a sense of uncertainty about the prognosis and the moral ambiguity related 
to its contested diagnosis.   
Living with a chronic condition was life changing not only for the patient but for their family 
and friends. Although patients shared views of support from families and friends, some 
reported their illness was not recognised as real, which resulted in feeling unsupported by 
those closest to them. As one female patient described: 
“I mean, even the supportive people like my husband and my mother were 
sort of like, you just kind of need to buck up and you know, try a little 
harder [...] you just need to quit whining and put your happy face on and 
act like everything’s going to be okay and it will be okay and I was like, 
you don’t understand what kind of tired I’m talking about”. (Rebman et 
al. 2015 p.7) 
The invisible nature of the illness and the lack of legitimacy from being without a diagnosis 
made relations with friends and family difficult for some patients. Patients described 
responses to their condition as isolating and upsetting:  
“It’s hard enough when you’re declining and you get everybody’s love and 
support. But to do it without anyone believing you is I think one of the 
most difficult things to deal with, as far as the psychology of the illness.” 
(Rebman et al. 2015 p.7) 
Patients were also affected by uncertainty about the trajectory of their unrecognised 
condition; general uncertainty about the course of the condition could be compounded by 
a lack of support and recognition from the medical community:  
“I live in fear, am I going to be a cripple?  Am I going to go nuts?” (Rebman 
et al. 2015 p.8) 
3.4.7 Theme 5: Contesting the contested - “So you really have to educate yourself and 
everyone around you…” (Drew and Hewitt 2006 p.24)  
 Patients challenge their lack of official diagnosis by seeking alternative 
solutions, education or by joining or forming self-advocacy groups. 
 Patients sought diagnoses from alternative sources to achieve some legitimacy for 
their experiences. 
Patients discussed the importance of self-advocacy to educate themselves and others (Drew 
and Hewitt 2006).  
“So you really have to be your own advocate… and educate yourself and 
educate everyone around you so that people are aware. In fact, all along 
I had to be my own advocate.” (Drew and Hewitt 2006 p.24)  
Additionally, patients questioned the knowledge of the doctors, as reported in Bloor and 
Hale (2013); 62% of survey respondents did not think their general practitioners were fully 
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informed about infections from ticks and 63% believed NHS consultants did not have the 
required expertise to deal with the infection.  
“I was tested early and it came back negative. They spent the next one 
and a half years trying to say I had MS, until a consultant suggested 
retesting for Lyme. That test was positive. Now if the doctors who saw 
me (and there were many) had any knowledge about Lyme they should 
have realized tests come back negative if tested early in the infection, 
because the body has not yet produced antibodies.” (Bloor and Hale 2013 
p.6). 
Patients also expressed uncertainty about the accuracy of serological tests (Bloor and Hale 
2013, Dankyi 2016, Drew and Hewitt 2006, Johnson et al. 2014). For example, Johnson et 
al. (2014) mentioned that most patients had co-infections with other types of tick-borne 
infections, which made test results difficult to analyse. This mistrust of diagnostic tests led 
patients to challenge test negative test results:-  
"What do you mean, she doesn't have Lyme? I see something on here that 
says positive." (Dankyi 2016 p.66) 
From Bloor and Hale (2013)’s survey, 56% of respondents reported negative officially 
recognised test results; though by responding to the survey they indicate that they still 
identify as having Lyme. Both Bloor and Hale (2013) and (Drew and Hewitt 2006) discussed 
patients who had a diagnosis of Lyme disease but, initially, had negative test results. 
Likewise, the majority of respondents (58.7%) in Johnson et al. (2010) derived their diagnosis 
from tests that were not the medically recognised diagnostic tests for the disease.  
These difficult relations led patients to seek other providers. Some sought out providers who 
adhered to different medical guidelines than those developed by the Infectious Diseases 
Society of America (IDSA) (Johnson et al. 2010). These doctors were described by study 
authors as ‘Lyme literate medical doctors’ (LLMD) and were willing to diagnose and 
prescribe long courses of antibiotics, if necessary, according to the guidelines set out by 
ILADS (International Lyme and Associated Diseases Society), seen as an alternative at the 
time of the included study (Johnson et al. 2010). Complementary and alternative medicine 
was taken up by others, since these therapies enabled patients to manage their symptoms 
(Ali et al. 2014). 
Thus, the patients describe a range of strategies to counter their experience of denial and 
dismissal by clinicians based on contested guidelines and their efforts to reinforce the 
concept of chronic Lyme disease as a legitimate condition. 
3.4.8 Patient advocacy group views on these findings 
Patient advocacy group feedback on these findings from both the face-to-face consultations 
and the online survey is reported below. For many of the stakeholders who attended the 
face-to-face consultations the overall findings from the research on patient views were felt 
to resemble their own experiences. Some stakeholders explicitly noted that the themes 
from the research covered many key issues, for example, ‘there’s a lot of it covered there’. 
Given the lack of research from the UK, the similarity of the research findings with UK 
experiences was unexpected for one stakeholder, ‘I was wondering how well it would 
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correspond with the British experience and it does. It’s highlighted all of the main 
problems.’  
 
In addition, the stakeholder feedback also indicated that the five main themes from the 
patient views research were appropriate; in many cases they provided additional insights 
about these themes.  
Feedback on patient views Theme 1: The difficult journey to obtaining a diagnosis 
Many stakeholders recognised the often fraught and emotionally charged nature of obtaining 
a diagnosis for Lyme disease. Some described the relief of receiving a diagnosis. However, 
many stakeholders described the ‘frustration’, ‘fear’ and ‘trauma’ of uncertainties 
surrounding diagnosis. Stakeholders strongly expressed a view that diagnosis is delayed as 
all symptoms are not considered together; all eight patient groups commented on this. For 
example, one clinician described multi-disciplinary working as ‘key’ and several patients 
described being ‘pushed from pillar to post’ around different specialist departments and 
that ‘no one is in charge’. One stakeholder described frustration with this experience:- 
“When you go to the cardiologist you’re just a heart, and when you go to 
the dermatologist you’re just a piece of skin. You’re not going to twig Lyme 
disease like that. It’s like the fairy tale of the wise men and the elephant, 
nobody will look at the whole patient.”  
A related issue, highlighted by several stakeholders as missing from the analysis of research, 
was the issue of misdiagnosis. Receiving an incorrect diagnosis for an alternative illness was 
noted as further delaying the diagnosis of Lyme and therefore appropriate treatment. One 
group shared findings from their survey of UK patients self-identifying as having Lyme, which 
indicated that many of their respondents had initially been diagnosed with one of 37 
alternative conditions. One stakeholder pointed out that many of the alternative conditions, 
such as Chronic Fatigue Syndrome and Fibromyalgia, are labels which describe people’s 
symptoms and leave patients feeling deflated as the root cause of the problem is not being 
established.  
Feedback on patient views Theme 2:  Ambivalence from clinicians  
Participants from all eight patient advocacy groups described a view that patients were 
denied diagnosis by sceptical clinicians. These clinicians were described as explicitly 
denying the existence of persistent symptoms of Lyme disease or informing patients that 
they ‘don’t deal with Lyme’. Some stakeholders indicated this theme as particularly 
relevant, for example ‘What has hurt me just as much [as my illness] is the way we are 
treated’. Others stressed the fact that the consequences of doctors’ scepticism were severe 
for patients, i.e. little or no support and treatment. Some felt clinician scepticism arose 
because their symptoms were not immediately visible; many indicated parallels to other 
contested illnesses with few visible symptoms such as Chronic Fatigue Syndrome. Some also 
contrasted their experiences against those with very visible symptoms such as acne ‘We’re 
giving people with acne a longer course of doxycycline than we are Lyme patients at the 
moment’. Stakeholders also indicated that relations with clinicians were fraught as a result. 
This was not only because patients experience ‘a system of disbelief’ but because they also 
experience clinicians as condescending and dismissive.  
30 
“Infectious diseases laughed down phone when given my private test results. 
Not just not believed, but laughed at and ridiculed.” 
The research indicated that patients felt clinicians who regarded persistent symptoms of 
Lyme to be a psychological problem undermined them by suggesting their problems were 
not a genuine physical illness; many stakeholders agreed with this. For example, ‘The 
attitude is “Things that I can’t explain or things that I haven’t got a test for just call it 
psychological.” And that happens over and over.’ A related theme which was not described 
in the research was a questioning of parents’ sanity when they believed their child to be 
suffering from symptoms of Lyme disease; several stakeholder groups noted that some 
mothers were being diagnosed as having Munchausen syndrome by proxy (MSBP). 
It should be noted that whilst many of the participating clinicians recognised themselves as 
more ‘open-minded’ in relation to persistent Lyme disease symptoms, many also recognised 
the difficulties clinicians face in diagnosing and managing those with complicated symptoms 
and unclear laboratory findings.  
Feedback on patient views theme 3: Practical consequences of living in limbo  
The third theme arising from the patient views research was that patients with persistent 
symptoms, and particularly those without an official diagnosis, could experience negative 
consequences with regards to their livelihoods. 
Emotive descriptions were given of the very real impacts on the lives of those living with 
disabling symptoms. Stakeholders described patients having to sell or re-mortgage their 
homes in order to pay for private treatment. Others described the impact on their careers 
‘when you fall off the career ladder… you can’t get those years back!’ The significance of 
this issue for patients was emphasised by one stakeholder:- 
“That’s probably the single biggest factor that is ruining lives, is that they 
can’t function and they can’t remain financially independent, and they’re 
not given support. They’re just cut loose by the state.”  
Beyond financial and employment consequences identified in the research, the life-changing 
impact of patients’ unresolved symptoms was indicated by several stakeholders. For 
example, some described families breaking up under the strain of caring responsibilities and 
others expressed concerns about being able to have children ‘I’ve lost the right to have 
children and everything – because of a disease that’s not being treated.’ 
Many groups also agreed with the findings about negative impacts for society because of 
delays to diagnosis and the consequent lack of treatment. For some this weighed heavily:- 
“We’re going to cost the NHS more money if nothing is done. Last year I went 
to hospital 36 times. I’ve got surgery on Thursday because of the damage 
that has been done. I’ve been out of work, I can’t give anything back to the 
country.” 
Others pointed out that there are likely to be hidden costs related to misdiagnosed and 
undiagnosed cases with countless visits to clinicians, consultants and numerous tests to 
eliminate other diseases. 
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Feedback on patient views theme 4: Emotional consequences of living with a 
contested condition 
The fourth key theme arising from the research for patient group stakeholders was the 
emotional costs for patients of living with a condition that they feel is poorly understood, 
not recognised and even contested by many clinicians.   
Most of the groups agreed that in addition to living with persistent disabling symptoms, 
living with a contested condition has emotional consequences, for example:- 
“I can’t put into words the level of suffering you experience, and at the 
same time as having to navigate all this judgement about your treatment 
choices. It’s a really desperate situation.” 
In common with the research findings there was a recognition among stakeholders of the 
negative impact of this on families – ‘When you have doctors calling patients into question 
families don’t know what to do’ – and the knock-on impact on patients of family members’ 
uncertainties. However, several stakeholders noted a related mental-health issue that was 
not clearly identified in the research. They described how patients’ mental health could be 
affected both by not being believed and by the infection itself. For example:- 
“The psychological component, people are really upset by it. But a lot of 
people start completely mentally healthy but end up with problems; it could 
be due to neurological complications but the trauma of whole thing could 
possibly contribute.” 
Many stakeholders referred to serious cases of mental ill-health among patients with ongoing 
symptoms; several referred to cases of suicide. 
Feedback on patient views theme 5: The challenges inherent in self -advocacy 
The final key theme from the patient views research was that many patients felt compelled 
to inform themselves and others in order to challenge the views of clinicians who were 
sceptical about persistent symptoms of Lyme disease.  
Many stakeholders discussed their view that evidence does not support the accuracy of 
diagnostic tests. In some consultations these issues were discussed at length. Unsurprisingly, 
the patient stakeholders also agreed with the need for self-advocacy. However, they further 
illuminated how the need to advocate could have negative consequences. For example:- 
“I agree with the literature, people find themselves in position where they 
have to push, argue or confront. But this makes them appear in a certain 
way.” 
This dilemma was also alluded to in another consultation in which it was noted that coming 
armed with information was not always welcomed by clinicians, ‘You’re dismissed as going 
to doctor Google.’ Some advocacy groups described advising their members on how to 
advocate successfully, for example by printing out PHE guidelines and taking them to the 
clinic to illustrate that, in the instance of an erythema migrans rash, further tests are not 
required for a diagnosis.  
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Several stakeholders described a view that marginalised groups would be more easily 
dismissed and therefore far less successful at self-advocacy. One stakeholder described 
being aware of only two patients who had successfully negotiated access to benefits, and 
noted that both of these patients were highly educated. This same stakeholder was also of 
the view that those with autism or mental health problems were likely to be the most 
disadvantaged in terms of accessing support or benefits. Another stakeholder described a 
view that women are more likely to be dismissed by clinicians than men.   
3.5 Comparing these findings 
The themes arising from each of these different types of research study (researcher 
arguments, clinician experiences and patient views research) were compared and 
contrasted, in order to discover where experiences converged or diverged. This is illustrated 
by Table 1 below:  
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Table 1: Comparison of themes from each type of study 
Themes arising/ 
Study type 
Themes arising from Researcher 
arguments in DTA studies 
Themes arising from studies of 
Clinician experiences 






























































































































































































































Researcher arguments in DTA 
studies 
    -- -- -- -- -- -- -- -- 
Studies of Clinician experiences  --  --         
Studies of Patient views  --  --         
 convergent theme  -- theme not addressed by study type
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3.5.1 Themes arising from studies of researcher arguments 
Four themes were identified in the set of studies examining researcher arguments for DTA 
studies. These are described below. 
Gaps in the evidence base 
This theme was only identified in this type of study, focusing on addressing gaps in tests 
related to geographic differences and a need for tests focused specifically on children.  
The remaining three themes were addressed within findings across all three types of study.  
Lab tests inaccurate 
There was agreement across all three types of research that current serological tests for 
diagnosing Lyme disease have limitations. Researchers conducting DTA studies most often 
argued that evaluations of the clinical or serological tests were needed because of a high 
prevalence of either false positives or false negatives in the current standard tests, as well 
as difficulties in subjective interpretation of lab results. This ambiguity was echoed in the 
studies of clinician experiences, where clinicians expressed doubts about the validity of test 
results, and infectious disease specialists in one study expressing concerns about high rates 
of false positive results due to a lower threshold for the serological test in use. The studies 
of patient views of diagnosis suggested that patients were concerned about false negatives 
and there was a belief that serological tests may not be capturing everyone who might be 
infected.  
Test interpretation and Timing 
Findings from all three types of research also suggested that both the timing of serological 
testing and the interpretation of those tests created difficulties. Researchers argued that 
current lab tests could be ambiguously interpreted, and that outcomes were affected by 
the length of time between tick bite and administration of the serologic test to detect 
antibodies. Studies examining clinician experiences reported concerns about private 
laboratory testing because the labs set a lowered threshold for positive diagnosis of Lyme 
disease, resulting in more consultations for patients who they believed did not have Lyme 
disease. The timing and interpretation of tests were also raised as a concern in the patient 
views studies and by the patient stakeholder groups.  
Varied symptoms 
The wide variation in symptoms of Lyme disease was identified in all three types of research. 
For example, researchers cited a need for new or improved serological tests to accurately 
detect the varied manifestations of Lyme disease. Studies of clinician experiences noted 
that common manifestations of Lyme disease such as erythema migrans were correctly 
recognised by clinicians, but only where they frequently encountered it. These studies 
reported that clinicians’ knowledge and adherence to recommended management of Lyme 
disease with less common symptoms was lower. Studies of patient views indicated that the 
variation in symptoms could be a problem for patients in gaining access to Lyme disease 
tests and treatment.   
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3.5.2 Themes arising from studies of clinician experiences 
Three themes were identified from the studies of clinician experiences: familiarity and 
expertise, dealing with diagnostic uncertainty, and navigating uncertainty. Aspects of each 
of these themes were also addressed in the patient views studies but were not located in 
researcher arguments. 
Familiarity and Expertise 
Familiarity with Lyme disease varied across the studies of clinician experiences. Most studies 
suggested that clinicians who see more cases of Lyme disease have higher knowledge scores 
and diagnose according to recommended guidelines more than those who see Lyme disease 
less often. However overall knowledge of Lyme disease etiology, epidemiology and 
diagnostic processes were still well below 100% in any group under study. Studies of patient 
views suggested that patients picked up on this, and clinicians were often described by 
patients as having low levels of knowledge.   
Dealing with Diagnostic Uncertainty   
Within this theme, findings in several studies suggested concerns about overdiagnosis. 
Clinicians in some studies appeared to attribute patients’ presenting symptoms to conditions 
other than Lyme disease and some sought to put an end to multiple consultations and 
delivery of treatment they deemed unnecessary. By contrast, studies of patient views 
reported that they were concerned about underdiagnosis and gaps in clinicians’ knowledge 
concerning uncommon symptoms.   
Navigating Uncertainty 
In order to navigate these uncertainties, clinicians reported using a range of sources to help 
them diagnose. These included external sources such as websites, other professionals, and 
continuing education opportunities. Some clinicians also report co-investigation with 
patients, who bring information with them to the clinical encounter. Whilst patients in the 
views studies did describe the need to do independent research on Lyme disease, feedback 
on these findings from UK patient advocacy groups suggested that they experienced 
clinicians as being defensive in the face of patient knowledge and advised them not to 
educate themselves on the internet.   
3.5.3 Themes arising from studies of patient views 
The difficult path to diagnosis 
Studies of patient views suggested that obtaining an accurate diagnosis was often a 
frustrating and lengthy process. The studies of clinician experiences noted that some 
clinicians were uncertain of what to do with patients who had a negative test result.  
Ambivalence from clinicians 
Studies of patient views described clinicians’ responses as ranging from helpful and 
supportive to dismissive or even hostile. Patients also suggested that they felt undermined 
by clinicians who ascribed a psychological cause to their suffering. Some clinician studies 
noted that when patients presented with symptoms or markers outside of current 
understanding of the disease they would treat them despite not believing that their 
symptoms were due to Lyme. Others described trying to convince patients that they did not 
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have Lyme disease because they did not meet the established criteria. Some described 
taking the latter approach order to alleviate the suffering they perceived their patients to 
be experiencing due to multiple consultations for a diagnosis of Lyme disease.   
Emotional consequences of living with a contested diagnosis  
Living with a chronic condition created uncertainty, worry and lower quality of life for 
patients. Authors and patients in the views studies called for the value of patient experience 
to be recognised. In contrast, studies of clinician experiences focused on doctors’ knowledge 
of and adherence to the correct diagnosis procedures, rather than their ability to meet 
patients’ emotional needs. Nevertheless, since some clinicians described prescribing 
antibiotics to patients who they believed did not have Lyme, there is an indication that they 
may have had an awareness of patients’ frustration.  
Practical consequences of ‘living in limbo’  
Patient views studies described considerable personal financial difficulties resulting from 
multiple visits to different specialists without achieving diagnosis or treatment or paying for 
private treatment not covered by health insurance. Patient advocacy groups also described 
concern about the costs to society because of unproductive healthcare use. These themes 
were also expressed in the clinician studies, where specialists expressed frustration at the 
increased number of referrals of patients with non-accredited tests. Some also acted to stop 
treatment that they considered unhelpful and possibly harmful to the patient.  
Contesting the contested 
Studies of patient views highlighted the self-advocacy role that patients adopted in order 
to challenge sceptical clinicians or inform those lacking knowledge. However, studies of 
clinician experiences reported a somewhat more positive relationship, noting examples of 





4 Discussion and conclusions 
4.1 Summary of findings 
Below we summarise the findings in order to address the two review questions: 
1. What are patients’, clinicians and researchers’ views and experiences of Lyme 
disease diagnosis?  
This review sought to understand the perspectives and experiences of three types of 
stakeholder with respect to Lyme disease diagnosis. Several common themes emerged across 
the diverse evidence-base of different stakeholders’ experiences. The themes largely 
resonated with UK-based patient advocacy groups.  
Many of the emergent themes indicate that there are significant uncertainties among 
stakeholders surrounding the two key approaches for diagnosing Lyme disease: (1) 
laboratory testing and (2) diagnosis via signs and symptoms.  
Evidence from each of the different stakeholder groups indicates a widely-held view that 
laboratory tests for Lyme disease are inaccurate. All three types of stakeholders described 
issues with false positives (overdiagnosis) and/or false negatives (underdiagnosis). The 
stakeholders’ perceptions appear to be in line with findings from systematic reviews 
examining the accuracy of diagnostic tests (Leeflang 2016, NICE 2017). Related to this, 
difficulties with the interpretation and timing of tests were noted in all three types of 
research. Uncertainties surrounding diagnosis via signs and symptoms were also recognised 
by all three types of stakeholder. Researchers, clinicians and patients noted that the wide 
range of symptoms and varied progression of the disease pose challenges for diagnosing and 
treating Lyme disease.   
The syntheses also suggested that the uncertainties surrounding Lyme disease diagnosis 
approaches were compounded by low-levels of knowledge among clinicians. This also raised 
questions for participants about the competency of the clinicians with whom they consulted. 
Inevitably these uncertainties were experienced as having significant negative impacts. 
One key impact was that these uncertainties appeared to undermine clinician-patient 
relationships, which has been noted elsewhere (Netherlands 2013):- 
‘In the event of persistent symptoms or uncharacteristic complaints, the 
picture becomes more complex and both patients and physicians are 
occasionally affected by increasing uncertainty. This uncertainty may 
then, in turn, cause some awkwardness in the consulting room, with both 
parties being keenly aware of a lack of common viewpoints.’ (Health 
Council of the Netherlands 2013 p.81) 
The quality of the provider–client relationship is often highly variable. However, it can play 
an important role in accessing appropriate diagnosis and treatment (Stevenson et al. 2004). 
Our synthesis of patient views suggests that patients with uncommon or persistent 
symptoms, especially in the absence of positive laboratory tests, experience difficulties and 
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delays in obtaining a diagnosis and treatment. Findings from the studies of clinician 
experiences indicate that the underlying uncertainties impact on their ability manage these 
cases sensitively and productively.  
An awareness of a ‘lack of common viewpoints’ was clearly evident in both the patient 
studies and from patients and clinicians who participated in our advocacy group 
consultations. Consultation participants suggested that, in addition to the breakdown in 
clinician-patient relationships, the awareness of a lack of common viewpoints has wider 
impacts. They reported that this awareness of polarised opinion surrounding Lyme disease 
hampers knowledge about Lyme disease as it deters researchers and clinicians from 
conducting investigations in this area. Controversy over research in the area of Chronic 
Fatigue, also a highly contentious condition, perhaps illustrates these challenges (Geraghty 
2016).  
A second negative impact of the uncertainties surrounding Lyme disease diagnosis that was 
reported in both the clinician and the patient views studies was the costs associated with 
unproductive healthcare use and costs to society. Despite a lack of common viewpoints 
about Lyme disease itself, the different stakeholders appeared to concur that uncertainties 
led to increased healthcare use and knock-on costs for individuals and society. Multiple 
consultations and the associated fragmentation of care are recognized to result in increased 
costs to patients, increased burden on health and laboratory services and increased risk of 
medical errors and adverse events (Bourgeois et al. 2010, Frandsen et al. 2015). 
The review findings thus suggest that researchers, clinicians and patients all recognize that 
there are significant uncertainties surrounding the diagnosis of Lyme disease. Both patients 
and clinicians also recognize that these uncertainties can result in significant negative 
impacts.  
2. How do these perspectives and experiences help us to understand and implement 
findings about the accuracy of different diagnostic approaches?  
This review was designed to help interpret the findings of the reviews undertaken by NICE 
on the accuracy of diagnostic tests, in order to aid the use of these tests in practice.  
Findings from our review suggested some possible approaches for mitigating the problems 
different stakeholders experience around Lyme disease diagnosis. For example, our review 
suggests that patients and clinicians could acknowledge diagnostic test inaccuracies and 
consider together the limitations of tests. Co-investigation/shared decision-making may 
help patients and clinicians work together to tolerate uncertainties in diagnosis. This will 
help both stakeholders to establish a plan for proceeding with further observation, testing, 
treatment or referral (Politi 2011). Similarly, NICE guidance recommended (NICE 2017c) to:  
 Discuss with the person the accuracy and limitations of the different tests for 
diagnosing Lyme disease. 
 Explain to people being tested that most tests for Lyme disease assess for the 
presence of an immune response (antibodies) to borreliosis infection, and that the 
accuracy of blood tests may be reduced if: 
o testing is carried out too early (before antibodies have developed) 
o the person has reduced immunity which might affect the development of 
antibodies. 
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 Advise people that tests available privately (including from overseas) may not have 
been fully evaluated or meet the standards needed to diagnose Lyme disease. 
Findings from our review and from the NICE reviews highlight multiple uncertainties 
surrounding Lyme disease diagnosis. This suggests a need for a considerable depth of 
clinician knowledge. The constantly evolving understanding of the etiology and 
epidemiology of Lyme disease in the UK and worldwide also suggests that clinicians must 
update their knowledge regularly. While understanding of UK clinicians’ knowledge is 
unknown, training opportunities for medical students and continuing professional 
development exist. For example, the Royal College of General Practitioners has developed 
an e-learning package on Lyme disease, in collaboration with Lyme Disease UK (Royal 
College of General Practitioners and UK 2014). Such resources are thus available for wide 
integration into medical education. These could be developed in collaboration with patient 
groups and modelled on training efforts in countries where Lyme disease is more frequently 
diagnosed. Related to this, the uncertainty created by the wide variation of symptoms 
experienced by patients, the lack of consistent clinician knowledge and the lack of accurate 
tests could perhaps be acknowledged more openly when discussing options for managing a 
patient’s symptoms.    
The findings around strained patient-clinician relationships suggest that maintaining a good 
relationship is key to addressing patient symptoms and the impact these have on people’s 
lives (Conboy 2010). In the absence of evidence from those who are infected with Lyme 
disease and recover, it may be assumed by providers that for many patients, current 
practice is effective in managing this presentation of Lyme disease. However, those people 
who present with a more complex set of symptoms, or whose symptoms are not recognised 
and managed appropriately, must also be given consideration to ensure their needs are also 
met. Rather than multiple referrals to specialists for specific symptoms, a more holistic 
approach to care is suggested. This could be take the form of care provided by a 
multidisciplinary team, with one professional designated as the lead provider for the 
patient.  
4.2 Strengths and limitations  
While this review is the first we are aware of that draws together findings from a range of 
stakeholders to present a broader picture of Lyme disease diagnosis, we note that there are 
gaps and limitations in the evidence base underpinning our findings on patient, clinician and 
researcher views. The available studies were of low to moderate methodological quality. 
With regards to gaps, most notably, there is a lack of UK-based research across the three 
types of study. Only one included study of patient views was UK-based (Bloor and Hale 2013), 
raising questions about the experiences of patients in the UK context.  
The UK evidence base on patient experiences of Lyme disease appears to be in the early 
stages of development. Several online surveys of UK patient experience were identified by 
the research team and more were provided by several public advocacy groups (Caudwell 
Lyme Disease 2016, Newton and et al. 2017, Tick Talk 2016, Viras 2014, 2015). However, 
we were unable to include most of them in the review because of limitations in reporting 
methods of sampling, data collection and analysis, which made it difficult to understand 
how the surveys were conducted and raised questions about potential sampling, selection 
and recall bias. The limitations in these studies demonstrate the challenges in building 
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capacity in citizen science, particularly around fostering public understanding about science 
communication (Bonney 2009, Research Council UK 2014, Selin 2016).   
It is unclear whether the experiences reported in the included patient views studies are 
generalisable to a wider population of patients with Lyme disease. All of the included 
patient views studies focused on people with persistent symptoms. However, despite both 
the non-UK settings and a focus on only part of the population affected by Lyme disease, 
patient advocacy groups described very similar experiences. Very few of the public advocacy 
group members we consulted reported a straightforward diagnosis of Lyme disease.    
With regards to clinician experiences of diagnosing Lyme, there were no UK studies and very 
limited qualitative evidence; only one of the nine studies used a qualitative research design. 
Studies of clinician experiences focused almost exclusively on measuring knowledge, 
attitudes, and behaviour related to the diagnosis and management of Lyme disease, often 
comparing against recommended guidelines to determine clinician adherence. While this 
provides insight into how well clinicians are able to diagnose Lyme disease in its common 
and uncommon presentations, a gap in understanding exists with respect to clinician 
experiences of managing atypical symptoms. Analysis of findings by type of clinician proved 
difficult. However, though we noted that a meta-regression of factors associated with 
knowledge/behaviours would be possible from this review, timelines did not allow us to 
conduct this analysis. This could add more information about how to appropriately target 
such a strategy.  
Consulting with UK patient advocacy groups helped to mitigate some of these weaknesses 
as it enabled us to assess the validity of our findings and their relevance to the UK context 
(Rees and Oliver 2017). In addition, inclusion of evidence from multiple stakeholders and 
multiple types of research study allowed a broad consideration of evidence that is suited to 
helping policymakers, clinicians and the public gain a holistic understanding of the complex 
issues involved in Lyme disease diagnosis (Rees and Oliver 2017, Thomas et al. 2017). 
Working closely with patient groups has helped to disseminate the findings in ‘real time’ 
and created relationships that will help us to explore future dissemination.   
Additionally, there were challenges due to working on a highly sensitive and hotly debated 
issue. Our concern was with reflecting the experiences and perspectives of each stakeholder 
group as equally as possible in order to foster understanding of the issues and try to build 
common ground for addressing the issues in future. We hope that this approach has allowed 
a balanced and equitable synthesis of the different stakeholders’ views, as far as the 
literature allows.  
Despite employing a systematic approach to reviewing this literature, to ensure the methods 
and findings are transparent and robust (Gough et al. 2017), there were some possible 
limitations to our review processes. The timelines for completion of this review meant that 
we had to have separate teams of researchers undertaking each of the four syntheses, each 
with different perspectives on the issue. This could have influenced our results but as a 
team we discussed emerging findings as each synthesis progressed. However, this may also 
have served to strengthen the findings by bringing a multidisciplinary perspective.  
The inclusion of ‘informal evidence’ (Sutcliffe 2015) for the researcher arguments synthesis 
is another possible limitation. Researcher arguments were extracted from the introduction 
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section of included DTA studies. We were motivated to conduct this additional analysis due 
to a limited amount of robust, synthesizable evidence from stakeholders (a limitation which 
is discussed above). However, they remain indirect representations of this group of 
stakeholders’ experiences and are thus a less robust form of evidence than research 
evidence that is potentially subject to bias (Enkin and Jadad 1998, Moore and Stilgoe 2009). 
Nevertheless, this innovative approach to understanding the issues from the perspective of 
researchers helped to increase the diversity and richness of the evidence-base. The 
triangulation of these perspectives against those of patients and clinicians also support the 
robustness of the findings. They can serve as a starting point to consider the perspectives 
of researchers well-versed in the issues surrounding Lyme disease diagnostic test accuracy.  
 
4.3 Implications 
Bringing together the research literature on patient, clinician and researcher experiences 
of Lyme disease diagnosis provides a starting point to understand the complex challenges in 
diagnosing this complex condition. The themes arising demonstrate that each group 
identifies similar issues with diagnosis, but that their perspectives differ. 
Several implications for future research arise from this synthesis. To inform our 
understanding of the full range of experiences of patients within the UK, a mixed-methods 
study comprising a survey of patient symptoms, their progress through diagnosis and a 
qualitative study of their perspectives of those experiences could be conducted. To 
ensure that the full range of patient experiences are explored, research should focus both 
on patients with uncommon or persistent symptoms and patients who present with erythema 
migrans rash, are treated and have symptoms resolve. This could be achieved by conducting 
qualitative research of the full range of patient experiences, and by including nested 
process evaluations in future trials of Lyme disease diagnosis. Qualitative research in 
particular would be strengthened by careful description of its epistemological stance, 
theoretical integration into the wider literature, and methodological considerations. Survey 
designs should include descriptions of sampling, facilitate higher response rates, and ensure 
control for confounders in analysis. Analyses should include examining differences in 
patients grouped according to: (1) the type of diagnostic method and (2) the clustering of 
symptoms. 
Similarly, research is needed on the perspectives of UK-based clinicians who diagnose Lyme 
disease. A mixed method study of UK clinician experiences of diagnosing Lyme disease 
could provide insight into knowledge gaps amongst clinicians from different specialties and 
with different exposures to Lyme disease cases using survey methodology. This should 
include qualitative exploration of clinicians’ experiences of diagnosing atypical symptoms 
of Lyme disease and chronic Lyme disease. 
This literature also suggests that there is room for clinicians and patients to work together 
in resolving the issues identified. This suggests a need for research methods to facilitate 
co-investigation of Lyme disease by patients and clinicians. This would help to identify 
the barriers and facilitators to effective co-investigation. Because each has considerable 
expertise in respective situational and differential diagnostic skills to bring to the situation, 
more effort could be made to make use of these strengths. This could also help to inform 
medical training and practice.   
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In the absence of evidence from those who are infected with Lyme disease and recover, it 
is unclear, but appears to be assumed by providers, that current practice is effective in 
managing this presentation of Lyme disease in the majority of these patients. However, 
those people who present with a more complex set of symptoms, or whose symptoms are 
not recognised and managed appropriately, must also be given consideration to ensure their 
needs are also met. Future medical education intervention development could draw on 
these findings and develop them further. We noted that a meta-regression of factors 
associated with knowledge/behaviours would be possible from this review, but timelines 
did not allow us to conduct this analysis. This could add more information about how to 
appropriately target such a strategy. 
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5 Detailed methods 
5.1 Aims  
The aim of this review was to understand the perspectives of those people involved in the 
diagnosis of Lyme disease within the UK context.  
5.1.1 User involvement 
We worked closely with the review’s commissioners throughout, in order to ensure that the 
review is closely aligned with their needs and emerging programme. In particular, we sought 
to identify research avenues that would support and complement the evidence being 
assembled by NICE in 2017 to produce a guideline for Lyme disease. 
We also convened a scientific advisory group (AG) of leading experts, seeking to obtain a 
balance of specialist expertise and a range of perspectives. The group was comprised of UK 
and national academics who have published on a range of issues relating to Lyme as well as 
representatives from Public Health England. The AG were expected to provide advice on an 
as-needed basis with regard to technical issues relating to the research questions, concepts 
and definitions, as well as strategies for dissemination and impact. Their main contribution 
was to advise on a cut-off date for searching. Lastly, we ran a series of consultations with 
patient and practitioner groups to help interpret our emerging findings in relation to current 
UK experience. 
5.1.2 Review questions 
 What are patients’, clinicians’ and researchers’ perspectives and experiences of 
diagnosis of Lyme disease?  
 How do these perspectives and experiences help us to understand and implement 
findings about different diagnostic approaches? 
5.2 Methods 
To understand the research evidence on stakeholder experiences of diagnosis, we conducted 
a systematic review. This included several stages of searching, inclusion screening, data 
extraction, synthesis, and interpretation and communication of findings (Gough et al. 2017). 
5.2.1 Study identification and inclusion in the map 
The first phase of the project involved producing a systematic evidence map covering the 
whole range of research evidence on Lyme disease in humans (Stokes et al. 2017). The 
findings of the map were then used to populate the subsequent, more focused systematic 
evidence reviews, including this review on experiences of diagnosis. 
Given the broad scope of focus of the systematic map, the search strategy was sensitive, 
consisting in effect of a single cluster of terms for Lyme disease. Further details of the 
strategy and databases searched are provided in section 5, and an example search strategy 
is shown in Appendix 1. 
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To be included in the evidence map, studies had to meet the criteria set out in Table 6.2 
below. 
Table 6.2: Inclusion criteria for the systematic evidence map  
Criterion To be included in the map a 
study must:- 
Rationale 
Date Be published in or after 2002. Guidance from members of the scientific 
advisory group was to focus on recent research 
from the last 15 years in order to reflect 
current experiences and practices relating to 
Lyme disease.  
Language Be published in English 
Language.  
Since the team does not have the capacity to 
search for and examine evidence in all 
languages we will include only those available 
in English Language.  
Health 
condition 
Be about Lyme disease. Studies may focus on more than one condition 
but must include at least some focus on Lyme. 
Evidence Be an empirical research study 
OR systematic review. 
In addition to empirical studies, systematic 
reviews (i.e. reviews for which ≥ 2 databases 
were searched and inclusion criteria applied) 
will be included. Non-empirical evidence, 
commentary pieces, editorials and non-
systematic reviews will be excluded.  
Population Be about Lyme in humans. Whilst studies of Lyme in animals may provide 
some information with implications for human 
populations, the priority is to focus in on those 
studies directly addressing Lyme in humans.   
Focus Not be a biomedical study 
focusing purely on markers or 
mechanisms of Lyme disease 
within blood samples, tissue 
samples, or cells.   
The aim of the evidence reviews is to 
understand patient and clinician experiences 
of Lyme, rather than the underpinning 
biomedical processes and causative 
mechanisms, in order to support DH in future 
policy development.  
5.2.2 Screening for inclusion in the review 
To be included in this evidence review, studies had to be one of the following types:  
 A qualitative or quantitative study published in or since 2002 that reports patient 
views relating to the diagnosis of Lyme disease and which reports methods for data 
collection and analysis. 
 A qualitative study published in or since 2002 or quantitative study published in or 
since 2008 that reports clinician views, experiences, knowledge or behaviours 
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relating to the diagnosis of Lyme disease and which reports methods for data 
collection and analysis.  
 An evaluation of a diagnostic test for Lyme disease included in one or more of the 
NICE evidence syntheses published in or since 2008 that includes informal researcher 
views (i.e. not collected using formal research methods) about factors that help or 
hinder the use of diagnostic tests.  
 
Because the diagnostic test studies and the quantitative clinician studies focused on 
understanding of diagnostic tests in relation to guidance we required them to be published 
in or since 2008 to ensure the findings reflect current guidance. For qualitative studies of 
either clinician or patient views, as these experiences were more wide-ranging we employed 
a cut-off date of 2002, reflecting the advice from the scientific advisory group, as noted in 
Table 6.2 above.   
Screening criteria were applied hierarchically: each study had to meet a criterion before 
the next criterion was applied. Screening of all titles and abstracts for the evidence reviews 
was followed by retrieval and screening of potentially relevant full-text reports by two 
reviewers working independently, with differences resolved by discussion. 
5.2.3 Data extraction and quality appraisal 
Standardised tools were used to assess the quality of qualitative (Garside 2014) and 
quantitative (Wong et al. 2008) studies in the patient views and clinician experiences 
syntheses. Studies were judged to be of ‘high’ or ‘low’ quality depending on the number of 
criteria met. Researcher arguments studies were not quality assessed as they evidence used 
was authors’ arguments and informal observations rather than formal research.  
5.2.4 Synthesis  
Researcher arguments for rationale of DTA studies 
It was hypothesised that researchers’ reflections on the need for DTA studies may suggest 
barriers and facilitators to the use of these diagnostic tests. To understand these reflections, 
thematic synthesis was undertaken of relatively informal data in these studies, for example 
the hypotheses or insights reported in their introduction or discussion sections. This 
synthesis used a grounded, iterative approach, translating themes between studies (Thomas 
et al. 2017).  
Studies of clinician experiences 
Using framework synthesis methods, data from the findings of the studies on clinician 
experiences were coded into an analytic framework of knowledge, attitudes and behaviour, 
as these were determined to be the themes most likely to be examined in this set of studies. 
New themes were generated into this framework as they emerged from the data. Higher 
order themes were then derived from patterns in the data (Brunton 2017, Carroll et al. 
2011). 
Patient views studies 
To synthesise studies of patient views, we inductively coded patient views and experiences 
as expressed in direct quotes and study authors’ descriptions of participants’ views using 
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thematic analysis (Thomas et al. 2017). To understand the context of the studies we 
collected information about how the authors presented arguments about chronic Lyme 
disease; whether they mentioned clinical guidelines; whether and how they problematized 
clinical and serological diagnosis; and whether there was any potential for a conflict of 
interest among authors. We also focused on the diagnostic status of their sample, including 
who had diagnosed and the recruitment source of their participants.   
Synthesising across study types 
Findings were then integrated across the three types of research (i.e. DTA researcher 
arguments, clinician experience and patient views studies). This was done by comparing and 
contrasting themes arising from the analysis of each type of research. This mixed methods 
synthesis balanced the systematic consideration of each type of study on its own terms with 
the need for iteration and flexibility (Sandelowski and Barrosso 2006). 
5.2.5 Quality assurance  
Screening, data extraction and synthesis of studies were conducted by two or more 
reviewers. Two reviewers either extracted data independently or a second reviewer checked 
the extraction of a first. Reviewers discussed and resolved any discrepancies and worked 
together to refine emergent themes.  
5.2.6 Consultations patient advocacy groups 
In July 2017 we ran a series of face-to-face or telephone consultations with eight UK-based 
patient advocacy groups. Participants included both patients and clinicians. Through these 
consultations we sought to understand whether our initial draft findings resonated with UK 
patient experiences, and would therefore be useful in informing policy and practice in the 
UK. Participants were provided with information about the purpose and methods of the 
consultations. They were informed that individuals would not be named but that groups 
would be acknowledged in the report if they agreed. They were also informed that quotes 
would be used in the write-up but that they would not be attributed to any individual or 
group. Before taking part all participants were asked to sign a consent form acknowledging 
their agreement to take part. Consultations were scheduled to last approximately 90 
minutes, although some were shorter and some longer than this. The sessions involved a 
presentation of themes arising from our initial analyses from patient and clinician studies 
and participants were asked to then comment on whether or not these findings resonated 
with their experiences. Participants were also asked to identify any areas or themes that 
they felt were missing from our analyses. The sessions were recorded and notes taken. The 
write-up of the consultations was shared with the stakeholder groups to allow them to check 
for factual errors or missing details.  
 
In October 2017, following the completion of our analyses, we shared the key review findings 
with the patient stakeholder groups. The findings were presented as a series of bullet points 
via an online survey and stakeholder groups were invited to comment. We requested that 
each group provide a single collated response for their group. As one group was unable to 
meet this request we had a member of the research team who was not involved in writing 
up the consultation findings collate the response for this group. The collated responses for 
each group were then assessed to check whether the key findings resonated or not with 
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patient groups own experiences. Comments relating to the findings of this exercise are 
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Appendix 1: Sample search strategy 
 
1     exp Lyme Disease/ (9589) 
2     (lyme or lymes or lyme's).ti,ab. (9797) 
3     borreliosis.ti,ab. (3230) 
4     neuroborreliosis.ti,ab. (1024) 
5     (borrelia$ adj2 arthritis).ti,ab. (38) 
6     (erythema adj2 migrans).ti,ab. (1471) 
7     1 or 2 or 3 or 4 or 5 or 6 (12593) 
8     exp Borrelia burgdorferi Group/ (6501) 
9     (borrelia adj (burgdorferi or afzelii or garinii)).ti,ab. (7347) 
10     (b adj (burgdorferi or afzelii or garinii)).ti,ab. (4289) 
11     8 or 9 or 10 (8983) 
12     7 or 11 (14245) 
13     exp animals/ not humans/ (4279323) 
14     12 not 13 (11450) 
 
The following databases were searched:  
 ASSIA 
 British Nursing Index (BNI) 
 Cochrane Central Register of Controlled Trials (CENTRAL) 
 Cochrane Database of Systematic Reviews (CDSR) 
 Cumulative Index for Nursing and Allied Health Literature (CINAHL) 
 Database of Abstracts of Reviews of Effects (DARE) 
 Embase 
 Global Health 
 Health Management and Information Consortium (HMIC) 
 Health Technology Assessment database (HTA) 




 Social Policy and Practice 
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 Social Science Citation Index 
 Sociological Abstracts 
 
In addition, the following resources were searched for on-going studies, unpublished or grey 
literature:  
 ClinicalTrials.gov 
 Conference Proceedings Citation Index: Science 
 Conference Proceedings Citation Index: Social Science 
 EU Clinical Trials Register 
 ProQuest Dissertations & Theses: UK and Ireland 
 PROSPERO 
 WHO International Clinical Trials Registry Platform portal  
 
A search for guidelines on Lyme disease was carried out via the following websites: Health 
Protection Scotland, Public Health England, Public Health Wales, National Guideline 
Clearinghouse, NHS Evidence, NICE Clinical Knowledge Summaries (CKS), NICE website and 


































Records removed:  
N = 31,094 
Duplicates: N = 29,561 
Year and publication types: N = 1,533 
Criteria on which reports 
were excluded (Map full 
text) 
Exclusion 1 - Date: Published 
before 2002 
Exclusion 2 – Focus: Not 
Lyme, borrelia, borreliosis 
Exclusion 3 – Evidence: Not 
empirical evidence 
Exclusion 4 – Population: Not 
humans 
Exclusion 5 – Biological 
mechanisms/markers 
Exclusion 6 – Language: Not 
in English 
Exclusion 7 – Registrations of 
trials 
Exclusion 8 – Case Reports 
 
Criteria on which reports 
were excluded (Review full 
text) 
Exclusion 1 – Not ‘views’ or 
NICE DTA  
Exclusion 2 – No data 
(diagnosis views) OR no 
rationale (NICE DTA) 
Exclusion 3 – No data 
collection/analysis methods 
reported 
Exclusion 4 – Published pre-
2008 (DTA/quantitative 
views only) 
Exclusion 5 – Duplicate  
Total records 
N = 52,268 
Full reports included in descriptive map 
N = 1,098 
Excluded on abstract  
N = 13,621 
Exc 1: 84 
Exc 2: 2,462 
Exc 3: 4,289 
Exc 4: 4,216 
Exc 5: 2,504 
Duplicates: 66 
Total records screened 
N = 21,174 
 
Full reports retrieved and screened 
N = 7,553 
Diagnosis studies N=310 
 
Full reports not available:  
N = 29 
 
Excluded on full report  
N = 6,426 
Exclusion 1: 3,960 
Exclusion 2: 190 
Exclusion 3: 1,249 
Exclusion 4: 94 
Exclusion 5: 166 
Exclusion 6: 731 
Exclusion 7: 36 
 
 
Criteria on which reports 
were excluded (Map abstract) 
Exclusion 1 - Date: Published 
before 1980 
Exclusion 2 – Focus: Not 
Lyme, borrelia, borreliosis 
Exclusion 3 – Evidence: Not 
empirical evidence 
Exclusion 4 – Population: Not 
humans 
Exclusion 5 – Biological 
mechanism/markers 
Excluded from in-depth 
review N = 248 
Exclusion 1: 204 
Exclusion 2: 4 
Exclusion 3: 7 
Exclusion 4: 32 
Exclusion 5: 1 
 
 
Researcher arguments studies  
N = 33  
 
 
Patient experience studies  
N = 9 studies 
 
 
Patient experience studies 
N=10 reports of 9 studies  
 
 
10 studies not extracted  









Appendix 4: Characteristics of included studies: Clinician experiences (n=9) 
Study (Location) Aim Population sample Prevalence of 
Lyme in study 
region 
Bakken 2002  
(Wisconsin, USA) 
'the purpose of this study was to explore how 
physicians learn to diagnose Lyme disease so 
that a theory could be developed to identify 
variables that can be used to design 
educational programs that facilitate the 
accurate diagnosis of this disease...This study 
is based in a conceptual framework of 
experiential learning, situated cognition, and 
reciprocal determinism.'  
Physicians practicising within a range of settings 
N=9 physicians 
 
Reported characteristics: practice setting, years 







Brett et al. 2014  
(nationwide, USA) 
‘to characterize the frequency of tick-borne 
diseases in clinical practice and the 
knowledge of healthcare providers regarding 
their management’ 




Reported characteristics: Range of specialities, 
years of practice, region of practice (South, 





Esposito et al. 2013  
(nationwide, Italy) 
‘to verify the adherence of specialists in 
paediatric infectious diseases (PIDs) to 
diagnostic and therapeutic recommendations 
by comparing their approaches in non-
endemic and endemic areas of Italy’ 
Paediatric infectious disease specialists 
participating in the Italian Society for Paediatric 
Infectious Disease Registry of Lyme Disease – 
includes all hospital PID specialists in Italy 
N=162 respondents  
 
No description of characteristics of practitioners 





Ferrouillet et al. 2015  
(two communities, 
Québec, Canada) 
‘A descriptive study of Quebec family 
physicians was performed to describe their 
clinical experience related to Lyme disease, 





one with known 
infected tick 
61 
Study (Location) Aim Population sample Prevalence of 
Lyme in study 
region 
familiarity with practices regarding the 
diagnosis and management of cases to 
validate whether these practices are 
compliant with the most recent guidelines’ 
Reported characteristics: range of years in 
practice, first-line or second-line practice, 




Hansmann et al. 2014  
(unspecified 
locations, France) 
‘i) to evaluate the accuracy of serologic 
testing for Lyme borreliosis performed in a 
private medical laboratory (PML); ii) to 
evaluate the impact of these tests on the 
practices of infectious diseases specialists 
(IDS)’ 
Infectious disease specialists subscribed to the 
French ‘infection-flash’ mailing list 
N=93 respondents answered first stage survey 
N=49 respondents answered second stage survey 
 
Reported characteristics: Both male and female 
practitioners, range of ages, practice settings, 
frequency of consultation 
 
Unclear 




‘to determine physicians' level of awareness 
and knowledge of Lyme disease (LD) in a low-
prevalence area and whether physicians' 
practices align with current guidelines for 
treatment of LD’ 
 
Paediatricians, general practitioners and internal 
medicine specialists licensed to practice in the 
province 
N= 2040 respondents 
 
Reported characteristics: years in practice, 
location of practice, number of patients seen per 
week 
 




Hill and Holms 2015  
(state-wide, 
Arkansas, USA) 
‘to compare the knowledge and attitudes to 
the practice for diagnosing and reporting LD 
for primary care providers in Arkansas’ 
 
Paediatricians, internal medicine, general 
practitioners licensed to practice in the state 
N=984 respondents 
 
Reported characteristics: region of practice, 
practice specialty, years of practice 
Unclear 
Johnson and Feder 
2010  
‘to survey a random sample of Connecticut 
primary care physicians to determine 
Random sample of 33% of all primary care 
physicians in the state 
High 
62 
Study (Location) Aim Population sample Prevalence of 




whether they diagnose and treat patients 




Reported characteristics: type of physician, 
number of cases diagnosed 
 
Singh et al. 2016  
(regional, West 
Virginia, USA) 
‘to determine the distribution of reported 
cases of Lyme disease in the state of West 
Virginia and assess clinicians' knowledge of 
Lyme disease symptoms, diagnosis, and 
surveillance’ 
 
Clinicians from departments of Emergency 
Medicine, Internal Medicine, Family Medicine at 




Reported characteristics: specialty, number of 






























Brett et al., 2014 








registered with a 
national professional 
database -no random 
sampling from this 
database reported 
Yes (score 1) 
 
-type of provider, 
age, sex, location -
drawn from register 
which was described 
as verified by the 
AMA 






treatment of LD -
same questionnaire 
applied to all 
respondents -but no 
description of pre-
testing these new 
four questions within 
the full 
questionnaire 
No (score 0) 
 
-response rate 48.5% 





in type of 
provider, age, 
sex, high- or 
low-incidence 
setting 
No (score 1) 
Esposito et al., 
2013  
High risk of bias 
3/6 
 
Not applicable (score 
1) 
Whole population of 
paediatric infectious 
Yes (score 1) 
-practitioner 
behaviour Authors 
used a piloted survey 
questionnaire. Some 
No (score 0) 
children with LD; but 
their diagnosis was 
established by the 
same practitioners 
who were being 
Yes (score 1) 
N=176 PIDs sent 
emails n=52 replied 
that they had 
treated child with LD 
n=110 replied that 






Yes (score 0) 

































risk of recall bias 
possible. 
surveyed about those 
diagnoses. So no, not 
reliable. 
they didn't treat a 
child with LD n=14 

















Ferrouillet et al., 
2015 








sampling from a 
specific and 
potentially biased 
segment of the 
population under 
study 




on previous tools and 
pre-testing of 
instrument on a 
sample of five 
experts and 10 
Family Practitioners 
(FPs) before applying 
-questionnaire is 
reasonably described 
in terms of content -
method of 




on previous tools and 
pre-testing of 
instrument on a 
sample of five 




in terms of content -
method of 
establishing endemic 
No (score 0) 
(p.153) 'In total, 201 
general practitioners 
answered the 
questionnaire, for a 
participation rate of 
59% (ranging from 
28% to 100%)' -but 
not sure what this 
latter phrase means 
as the eligible 
number of 
participants 
No (score 0) 
Not reported 






























described on p.151 
and non-endemic 
regions clearly 
described on p.151 
Hansmann et al., 
2014 










No (score 0) 
Development and 
testing of 
questionnaire is not 
described -authors 
appear to have 
designed a 
questionnaire that 
acts to confirm, 
rather than test, 
their hypothesis 
No (score 0) 
Poorly described 
No (score 0) 
Response rate 19% 
for Survey 1 8% for 
Survey 2 
No (score 0) 
Not reported 
Yes (score 0) 
Not reported 
Henry et al., 2012 
Low risk of bias 4/6 
 




practice in province 
were eligible and 
contacted=whole 
Yes (score 1) 
Self-identified type 
of physician 







No (score 0) 
Response rate 32.2% 
No (score 0) 
Not reported 





























although they don't 
report testing it 
themselves once it 
was modified 
Hill and Holms, 
2015 
Low risk of bias 4/6  
 
Non-probability 
sampling (score 0) 
Authors describe 
using a 'convenience 
sample' 
Yes (score 1) 
Type and location of 
provider likely to be 
reliable and valid, 
since drawn from 
state practice 
register 
Yes (score 1) 
Previously developed 
and validated data 
collection tool -pilot 
tested on subsample 
No (score 0) 
Response rate 24.5% 














No (score 1) 




Random sample of 
licensed 
No (score 0) 
Independent 
variable: belief in 
the existence of 
No (score 0) 
No reporting of 
reliability or validity 
checks on how 
No (score 0) 
Response rate 39.1% 































High Risk of Bias 
2/6 
 
practitioners in one 
state 
chronic Lyme disease 
-measure was not 
validated nor was 
any reliability testing 
reported 
doctors made the 
diagnosis of Lyme 
disease, or chronic 
Lyme disease, in 
their patients - just 





Singh et al., 2016 
High risk of bias 
3/6 
Non-probability 
sampling (score 0) 




Yes (score 1) 
Previous 
questionnaire used 
Yes (score 1) 
Previous 
questionnaire used  
No (score 0) 
Can't tell; authors 
don't report how 
many were eligible 
to participate, just 
how many surveys 
they received 
No (score 0) 
Questionable - 












have it but no 
data reported 



























on this, nor is 






Appendix 6: Characteristics of patient views studies (n=9) 
Study 
Country (location) 
Focus  Author description of chronic Lyme 
disease 






Ali et al. 2014  
 
USA (Connecticut) 
‘Experiences of patients 
who identify themselves as 
having chronic Lyme 
disease’ 
‘A constellation of persistent 
symptoms in patients with or 
without evidence of previous BB 
infection’ 
Self-report – 















‘Lived experience of access 
to care of patients with a 
Lyme disease diagnosis’ 
‘The range of potential symptoms 
can be considerable (particularly at 
an advanced stage), and can include 
fatigue, musculoskeletal pain, and 
neurocognitive difficulties’ 
Self-report – 
diagnosis by a 
clinician – some had 
positive and some 
had negative NHS 











‘Social, cultural and 
environmental implications 
of the illness’ 
‘Lyme patients, especially those 
with “chronic” Lyme may experience 
random resurfacing of symptoms, so 
















related quality of life of 
patients with "organically 
unexplained symptoms"’ 
‘There is no evidence for ongoing 
infection with Borrelia burgdorferi in 
patients with prolonged subjective 
symptoms after adequate antibiotic 
therapy … “Chronic Lyme Disease” is 




rated as “organically 
unexplained” 
or “organically 













Focus  Author description of chronic Lyme 
disease 










& Washington DC) 
‘Lived experiences of 
families with children under 
26 years diagnosed with 
Lyme disease’ 
‘Currently, there are two treatment 
guidelines for 
Lyme disease published by the 
Infectious Diseases Society of 
America (IDSA) and International 
Lyme and Associated Diseases 
Society (ILADS) … Patients and their 
families find themselves caught 
between this silent war’ 
Self-report – 
children with a 
diagnosis of Lyme 
disease and under 













‘Lived experience of 
becoming diagnosed with 
Lyme disease’ 
‘The chronic form of Lyme 
disease is supported by 
epidemiological studies 
showing that 30—50% of patients, 
even if treated, later develop 
multisymptom disorders of 
fibromyalgia’ 
and/or chronic fatigue syndrome 
Unclear – ‘a home 
infusion 
company’s database 
of patients with the 













‘Challenges faced by Lyme 




between IDSA and ILADS over the 
diagnosis and treatment of Lyme 
disease has been uneven in terms of 
power and resources … the 
consequences of IDSA’s influence 













Focus  Author description of chronic Lyme 
disease 






not been studied on a national level 
in the United States’ 




‘Severity of chronic Lyme 
disease compared to other 
chronic conditions’ 
‘A proportion of patients with Lyme 
disease develop debilitating 
symptoms that persist in the absence 
of initial treatment or following 
short-course antibiotic therapy’ 














‘Patient experience of this 
medically contested 
condition’ 
‘A subset of patients (an estimated 
10%-50% in prior studies) reports a 
range of largely subjective 
symptoms after antibiotic treatment 
… When these symptoms persist for 
6 months or longer in otherwise 
healthy individuals, they meet a 
proposed case definition for post-
treatment Lyme disease syndrome 
(PTLDS)’ 
Patients at the 
clinical practice of 
one of the authors 
who met the case 





practice of one 
of the authors 
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Appendix 7: Quality assessment tool: studies of patient views and experiences  
 
Q1. What are the epistemological underpinnings of the study?  
(i.e. if the study is trustworthy, judged by whether or not the voices of participants come 
through)  
Are the design and execution appropriate to the research question?  
What evidence of reflexivity is there?  
Do the voices of the participants come through?  
Are alternative interpretations, theories, etc. explored?  
How well supported by the data are the conclusions?  
Are ethical considerations given appropriate thought?  
 
Q2. What theoretical aspects are considered by the authors?  
(i.e. whether an explicit framework shapes the design of the study, thus enhancing claims 
for generalisability) 
Does the report connect to a wider body of knowledge or existing theoretical framework?  
Does the paper develop explanatory concepts for the findings?  
 
Q3. What technical considerations do the authors make?  
(i.e. the methods of the study, full and appropriate description of the stages of search, 
background to the project, etc.) 
Is the research question clear?  
Is the research question suited to qualitative enquiry?  
Is the context clearly described?  
Are data collection methods and tools clearly described?  
Are data analysis methods clearly described?  





Appendix 8: Quality ratings of patient views studies (n=9) 
 












Ali et al. (2014)  NO PARTIAL YES 
Bloor and Hale (2013) NO NO NO 
Chaudhury (2016) PARTIAL YES NO 
Dankyi (2016) PARTIAL PARTIAL YES 
Drew and Hewitt (2006) NO PARTIAL YES 






































Csallner et al.  
(2013) 
Not applicable (1) Yes (1) Yes (1) Yes (1) Yes (1) No (1) Low risk (6) 
Johnson et al. (2011) No (0) No (0) No (0) Yes (0) No (0) No (1) High risk (1) 
Johnson et al. (2013) No (0) Yes (1) Yes (1) Yes (0) No (0) No (1) High risk (3) 
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